[go: up one dir, main page]

HUE031916T2 - Szubsztituált triciklusos vegyületek mint FGFR inhibitorok - Google Patents

Szubsztituált triciklusos vegyületek mint FGFR inhibitorok Download PDF

Info

Publication number
HUE031916T2
HUE031916T2 HUE13783125A HUE13783125A HUE031916T2 HU E031916 T2 HUE031916 T2 HU E031916T2 HU E13783125 A HUE13783125 A HU E13783125A HU E13783125 A HUE13783125 A HU E13783125A HU E031916 T2 HUE031916 T2 HU E031916T2
Authority
HU
Hungary
Prior art keywords
alkyl
halogen
membered
methyl
mmol
Prior art date
Application number
HUE13783125A
Other languages
English (en)
Inventor
Liangxing Wu
Colin Zhang
Chunhong He
Yaping Sun
Liang Lu
Ding-Quan Qian
Meizhong Xu
Jincong Zhuo
Wenqing Yao
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49486650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE031916(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of HUE031916T2 publication Critical patent/HUE031916T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Claims (9)

  1. i. (H) képietiï vegyülct
    vagy ennek gyógyszerészetileg elfogadható sója., ahol W jelentése NR<}; X jëktiiém €RBvagyN; R! jelentése H, MEAR!i, halogén és C.y3 a$% Er is .R? mindegyikének jelentése egymástól Eíggetíénül H, CM, C(ö)NRcRá és alkil kftaftl va» kiválasztva, aholm említett Cy? aikil adott esetben szubsztitaálva van halogén, OR*,-CM, MR*Rá -ás €(0)MR*R4 közöliegymástőíÎSggeifeftÜlkiválasztott i, 2 vagy 3sxubs^ibignssaS; vagy R2 és 8 azzal a szénatommal együtt, atmdyhez kapcsolódnak, 3-7 a 4-7 tagú hetetoőíkloalki'hgyüföí képaznek, amelyek mindegyike adót! estben Ci., halogénaikil, CM,'ÖR\ SIC, CtOW*. (.XOjNStfR* CCÖjORVOCíöjR*, C82(0}NRfiRá, NReR4, NReC(Q>R* és NRiC(ú.i(>)Cközül egymástól ftlggetlenü! kiválasztott 1,2 vftgy 3 szubsztituenssei: R4, Rs, ÍC\ R’ és :Rb mindegyikének jelentése egymástól függetlenül ül, halogén. Cm alkii, €>,$ alkeníl, Qos; alkinils C(j; halogénaikil, C„ )0 aril. C-, (ii eikloalkd, 5-10 tagú heteroaril, 4-10 tagé heterocikíoalkií, CM, íM*f, f»# C(O)Rl’\ UOjMlC'R”'. C{,0)0R“, OC(Ö)Rm, ÖC(0)NRe,K4i, NíC’R4’, NRcl€iü)R;:\ M^CtOpR^, MRctC(C))NR^Rm, Ci/-NRí!)RhÍ, C{•-NR*l)NR8lR<Si, NR<fC(~NR<<)MR''1R4', MiC'SífOR^, M«4iS(öfc|kw, MR*!lS{0)íNRSÍR4*. SíO)KM. SiUjNir'R41, S(OfeRw és S{0)jNRifRJf közöl egymástól tliggetkmill van kiválaszíva, ahol az «milieu CVs alkii, Cm elkenik Cm alktníl, CVm> #»l. (Vio oikloalkil, 5-íö tag# lieteröáril és 4-1Ö tagú heismeíklóalkll mindegyike adott esetben szubsztituálva van halogén, Ci4> aikil, C« al ke nil, 1\.„ aikmii, C«.* halogénaikil, CM, NíM, ORJ!, SRsl, C(OíRh\ C(Ö)MR"lR'is, CiO)ORsS, OC(Om!,i, OOíÖjNiC’R'1*, C{“:NR*5 )MRetR41, NfC’Ct --NR'-'lNlC’R41, NRV>R4\ NR^CfOjR**, MRe,C(0)0R*', MIC'CCOINR^R4’, MRciSfO)Rhi, NR0'StOljRi!i, NR<'S{0)iMRe,Rái, S(0)R,,l> SCOjNR^R* S(O^Rai és S(Ok>NR'!R’n kőz#l egymástól loggeílenü! kiválasztott 1, 2, 3, 4 vagy 5 sznbszbsztítuenssel; Rf jelentése 11, aikil, Cm alkeníl, 0>,„ alktníl, Cm* aril, Cwo cikioaikii, 5-íö tagú heteroaril, 4-10 tagú heterocikíoalkií, asil-C,..* aikil, O?.j0 eikloaikil-Ci.4 alkik (5-10 tagú heteroarll)-Cv< aikil vagy (4-10 tagú heterocikíoalkií)·CM aikil, ahol az emliteit C>„ aikil, Cm alkenii, €?..·, alkinil, €,.(.aril, Cs.!(, cikloalkil, 5-li tag# hetetmril 4-10 tag# heteroeikioaikii. C\.«, sril-C3..: alkik Cj.K, eikioalkil-Cj,,! aikil, (5-10 tagú hete:roaiil|-C}4 aikil és (4-H) tagó hetcTocikioalkiö-Cj.i alkii mindegyike adón esetben szubsztiiuâiva van R,a szdbszbsztímensék köztit egymástól függetlenül kiválasztott 1,2, 3, 4:vs0$ az R'ís -azu&amp;stdituenssek mindegyikének jelentése egymástól függetlenül Cy!, halogén. C,.* aikR C;.ft sikemí, Cw siklód, Cht> haiogénalkik CM, NO., OR*2, SRS\ C(Q}Rh\ C{0}NRcPa\ CIOIOR* OC(OpK;:, OaO)NRi?Rí?. CRNAnA**, NRciCO-'NR'")NRfP'l\ NRí2Rd\ ItApp85, NR*2C<Ö)ÖR*2« NR''ÍC{0)NR":;R'i;i, NReïS(0)Ri>2, nAíORR*'2, NR';S<0):NR‘"R"·', S(Opâ>\ StOpR^A S(0)Jiâ:î és S(0}jNR<?R<ß közül van kiválasztva, ahol az említett Q.« alku. Cm elkeniI és C.:,,h stlkinil mindegyike adott esetben szubsztítuáiva van Oy‘, halogén, ΓΝ, No,, OK*2. SRS\ C<0)RK\ aO)NRaR'JJ, ΐχθΚ»*% 0C(0)Rb?, OCíO)M4ÍR® C{~NR*2 )N R~R42. NRe2C<~NR*2}NRe2Rd2, MR%* nAXOR“ NR^CXOjÖR*2, NR0íC(O)NR<2R4\ NA(0}Rtó, NK^ÍOIP* íW^öfeNR**«*, S<0)Rb2, S{Ö)NReiR<ß, S{0}2Rü3 és SIOpíR^R^ közöl egymástól Riggeíienü! kiválasztott í,:2 vagy 3 embsziittteosseíí Ajeíeniéxe haló#«, €;*r«!kil» C?.« athéni!, Mm aikímS, C5.4· ha|0g4Ä% C&amp;m Ä -ÍSm« 5-10 tagé heteroanl, 4·· 10 tagú heterocikloalkil, CN. NO,, OR*3, SR*\ C®^£ppR^ OfÖpR*2, 00(0)11“ OC(0)NRe5Rá? , NR**Re, NRPïCOp85, NR^OPjOR;^, mcíC(0)N Aá5, C(-Nle3p>3:t Ci -NRf*5)NR<:íRíi\ NR‘:5C(~NR‘ ’)NR; 'R<( \ NRíJS(Ü)Rw, NR‘*S((%H#fcF, S(OjA S(ö}NR*,R'í\ $fÖ>.;Rb' és StOjjNir'K'*' közöl van kiválasztva; ahol az említeti Cp alkil; alketiil, síkin 11, Cvií, aril, O*.^. dkloaiLb. Ó-H) tagó hetemen! és 4-só tagú heterooíkloalkii mindegyike adott esetben szublimálva van Rl,!i> szubszbsztitaeméfe közül egymástól flggetSdíül kiválasztott 1,1, % 4 vágy 5 sznKyztliuensseí; R}í jelentése H, halogén, 0,.* alkíl, C« alkenil, CP alkími, €-¾.¾ halogénelkik €».«, aril, C}.w éikloaiklk 5~I0 tagú hetetteml 4-10 tagó heterodkloalkil. Í.N, NO,, OR*®« R#? €ίϋ}ΙΓ\ C(0}NA‘b, CpjOR*5, tiC(0)Rh\ OCí(.»NR°R";: , NR*V\ NRc<C{0}Rtó, NR^QGjGR^. NR*'‘t\0}NR*3Rdi, C(-NR^Ä P^NR^NA*, NR'’'<C{!S»NR*í)NK'’,Rá:,í nA<0)#\ m*P(Oj2A MR*3SPPHÄ*?s SiÖ)ßM, SPINR^R1*3, S{0}}Rhí és S(OhNRwRdí közül van kiválasztva; ahol az stnliieít CP aikd, Cp álkentl, €p slkümL C„ u, aril, Cm,·, eikleaikil, 5-3Ö tagó heteroarll és 4-10 tagú heteroeikíaaiktl mindegyike adott esetben szubszumálva van R10* szubszhsztí mernek közül egymásmi függetlenül kiválasztott % X 3, 4 vagy 5 szubsztítoensseí; Rw* jelentése npdegyik eUttordniási helyén egytnasiöl Siggntlettül Cy®, halogén, Cp.alkit, Cp aikenSí, Cm aiklnil, CP; áalógtóíkil, ÓN, NO>. OR*3, SR?3,. 0$%0t C(OpR^Rrf\ C(0)OR#, ÖC(Opb| ÖCÍGJNR^R**, OpNR^pA**, N ReíC< “NR*3)N'R'?'3R<ií, NR'!Rá:t> W2CÇI$Rf5, NR^CPjOR*, ÍNRcíC(0)N R^R^, HR^SPi#, :'NR'"‘S(0)?Rfc}, NR^SPfeNR*^, S(P®, SPPR#Rdí,. és SPlpP’R"3 RözP van; kiválasztva, ahoi az említett €t* aíkii, C2.ft aikenri m Cm aíklntl mindegyike adott esetben *zuhszíituáíva van ély3, halogen, ON, NDj, OR*2, SR*\ C(0)&amp;k\ 0|ÍpRsi#r CpjOR*0, 0C{O)Rb2,· OCfONR^R^’, C(“NRí3)NR‘ 5R^, NRí:!R*', NR.0€(O)OR*®, NR^QOlNlPíé® tlÄO)Sö, NRöSpiRB, HR^SÍORNR^R^, B(0)Rh\ S(OPRfc'R«\ és '^0)íNRs-fR^:;küzÖÍ:^!!^ástól ínggétlenül kiválasztott 1,2 vagy 3 szithsztituensael; R A és R^rnmdegyíkének jelentése egymástól Riggetlenül H, CM aikil, C-m haiogénaikil, C:(^ alkéml, alkinii aril, €*.»· cikloaíkik 5-1Ö tagú heteroaril, 4-iÖ tagö lietetocikioalkíí, Os.«, aril-Ct-« ÄiU Cm» cskloalkii-C^, álkil, p-IÖ tág« betoroarijj-Cj^ afktl vagy tagú heteroéikíoáikiij-Gní aíkíl közül van felyálásztva, aiiöt az émitfétt 0t4:Â|Pj^#kàil|,.C^:aîkMl, Ct..m ári!, Cpö élklealkii, 5-1Ö tág« hé£er0árli, 4--10 tagó hetemeiklöalkii, €¢..)(,aikt| C5<® e<kleaíki!p.4 aikil, (5-10 tagó heterearil.K').:< aikii és (4-10 atkttt esetben «zubsztituálva van OH, CH, amltm, halogén, älktj, Ot:.saík<otk C’iMslkilÖOv: di^C!}^ «Μΐ^ϋίίί», Cm haiogénaikil ës C'm haiogénalkoM: közöl egymástól h|ggëOë»ül kiválasztott 1,2 vagy 3 szubsztituenssel; Cy! és C\? mindegyikének jelentése egymástól ftggetlénöi Gö,!0 adj, €&amp;&amp; etkiöáíkih S IÓ tagé heteroarií, 4-4Ö tagú heierocüdoaíkil közül van kiválásivá» amefysk mindegyike adott esetben szubszaítnálva van háSögóíij iCi^ alkil, Qm alternd, 0:.¾ aikiitU, t'}.„ haíogénalkíi, 0Υ*0 aril. (.Yjo cíkioalkll, S-10 tagú beteroaríl, 3-10 lapu heietvoikinaíkii, CN, NU* OR'!\ SlCl 0(0)10', Cp)NR‘Pa\ (\tYiC>R*\ 0C{0)Rbí, OC{0)NRcíR<,í, kiR“V\ ΝΚνίι'(0)^\ NRS-(.:(0)010^ NRcV<0)NRíJRdi, CC“NRe,)Rfa5, CC-NR^NR^R0, $lRtíi'(-NlO')NR,':R,is, NRt5S(0)Rw, Mr5S(0):Rb\ NlG'SpVNR^R45, S{0)RÍiS, SCONR^R^, b(Q)2RÍ,s és S(G):NR'íSR'í' hozni kiválasztott 1, 2, 3, 4 vagy S sziibszliiuenssel, ahol a/, említett Cm a!M|. Cjt. alkenil, Cj,6 áikipk ar|| Oi.u, cikíoaikil S 10 tagó heteroarií és 4-10 tagú heterocikloalkil mindegyike adöti: esetben SMhsiituá!va van halogén, c, <, alkil, Cm alkotni, CM alkintl, Cm haíogénalkíi, 04, NO> 0R*\ SRa\ C(Op-, 0(0}NÍ#Ra\ C(0)OR8S, 0C(0)RM, 0e{0)NRs5Rdi, Ct- NR85)'NR8V\ ï4Ri>CX-NR'"'}NRc$Ra', NIC5!#, ÄsOYO)Rfe\ NiCYtOOR“5, NReiC(0)NR<'5R'!,f NR“5$í 0)Rb;\ NR<''5S(0)jRb··, NRlSSiO.|3Ä5:l#', $(<*ρω, S«UNR‘V\ Stop1* és S|0);íNR';5R!Í5 kö^üi egymástól függetlenül kiválasztat 1,,¾.% 4 vagy S síahskhsztStuenssel; R”, R\ R\ Rd, Rsi, Rw, Rsi, RJi, R“2, Rw, !0\ Rdí, R* Rw, Ra, Rri:<, R*\ RM. R'“ &amp;> R* mindegyikének jeteiése egymésíóf Oiggetíénii H, Cm 4Μμ£;,ΐ halogénaiklk Cm: áikeoih C2.„ alkinil, Co.J0 aril, Cmq éiklnaikls. :S-:l:ö :tagó: hetessiaril, 4*10 tagó hetemetkloaikíi, Cílvi0 aríl-C:M aîklïi Çj^e ukloalkü-O^ alkil, (5-10 tag«:heteroaril;)-0*4:alkíl, vagy (40 8 tsgö heíemelkioalki3)-CM: álkil közül van kiválasztva, ahol su említett slkii, alkentl, Ojís alkiöd, £%» atü,(¾ eifcíoalkíl, 5-dó t^gäihet^earRyJ^il' tagú hetsrocildoaJP, Qm* adM2{_ä alkil, Os^sikloalkihC)^ aíkíl, (S^töiagó hetémariil-Ci^ álfcít és- (4*1ö.mgó 'hetéföniklöáötlÜ^is*:^^ adott esetben szdbszíitöiíva van Cm alkil. Cm kâlogénalkli, halogén, CN, OR“”, SR“6, C(öp!>4, OppR^R4'’, CtO)OR:!Í’, OQOR* 0C(0)NRtbR*, NRc*R:i<>, NR“&amp;C(0)Rt* NRcP{0)NRï6RQ NR1P(Ü)0RQ Ct-NIC^NR^’R®1, NR^et^NiCONR^S1*4, S(Ö)RQ S(OVNrV(’, S(0)2Któ, NR“dS(0)yRbb,PR®%(©)2l4R':iSR;í<í és Rpl-NíQ’R®’ köKÖÍ e^másídÍdhggeíÍenikkíVálasxtotf 1,2,3,4 vagy 5 szubsteituenssek vagy bármelyik Re és R4 azzal az Id atommal együtt, amelyhez kapcsolódnak, 4», 0,44 vagy ?-tapi 6§fö«»éik.lö«fMkcsóp^f:Sáp«íek*:ajneÍy ado» őseiben sztiteiitttálvá Váii:¾ alkil, C(.-; cikloalkil, 4-7 tagú heierocik loaíkii, C^i0 anl, 5-6 tagú heseroanl, C;.Ä hálögenáílR, halógéig CN, OR“", SR:>t:. CtO’fR*1", CXONR^B46, C(0)0RsX 0C(0)Rb,>. CKXOiNR^R^V ΝΚ)60(Ο)Κ'·χ NRs6C(0)NR''f,R'i", NRc<,C(C»OR3·, CCddi^NR^R40, NirV(-NRtó)NR“Wy; SíOJNrP46, SiO)^, NRj6S(0)3RbX •hlR^SlOXíM R^R^és^^MR^R?* tözill egymástól ftíggetléníilkiválasktött 1, 2 vagy 3 sxabsztituenasel, ahol az említeti C;,* alkil:, Cs..? eikioalkíl, 4-7 tagá: hetepedkloalkík C(í,)ö et il és S-ó tagn lieteföädi adött esetben szabsztimáíva vsö halogén, CN, 0RSÍ>, #, Cp)ÍÍ:b, €(0)Ν10Χ140, C(0)ORa6, ΟΟξΟΡ66, CXpóNR^6. NlPiC'X NíPCpjR^» NRÍ7C(Ö)ÖRtó, CHdS^pR^MÍ®, HRc6C(“NR''!:‘)NRi<iR*i;>, SCOIR?6, SCOíR66, NXPtÜbR***, NR'-pCObNR^R46 és WßW®^&amp;M egymástél biggotienOi kivátesztott 3,2 vagy .XszöbsKÖttjenssél;: vagy bármelyik: Rr és Rdl azzal az N atoímsá! ggytln, κηοΐροζ kapcsolódnak, 4^, (G, b- vagy 7d:agá: heteröelkiöalkii-csöjmööt kép&amp;znek,: amely adó» eselbett aziibszíiíttálva vm Gp: alkil, C-g·? eíkloaikil, 4-7· tagé hetemclkioalkiS, C(i,í0 atil: 5-4 tag» beteroarii, Cos haíogénalkíi, halogén, 04, : OR45, SRä6, CCQp^, ßppÄ, C(0)OR,,<:', OCtO)«'-'’. OaOjNR^R^, NRe4R‘K', NRtAC(0)Ri:,>, NR^CXOINR^R“6, NRu><:íö)OR*'; Cl S^ipR^R®, SCOfcR* MRí4spptó, HR^iöYPR^R^ és S<0)pR'%^ kíkü! egymástól fitggetlenöí kïvéîàs^Î L 2 vagy 3 saibsztiíüenssék íáioi az említett Ci.*, alkií, Cx.-. elkloalktl, 4-7 tagú bete»Mk:iottlkt!, C^jo arii és 5-6 tagú heteroaril aúött esetben szuhsztiiuáiva. van halogén, CN. OR* SR*\ GO)í&amp;, C{0)NR*R*\ CCOJOR* OC{ú)KH\ OCiONR^R*1, art** ΝίΓ*αο)κ^, mäöpr^r*, Nrte(o>oR*i .MR^pM^g»*, m>)&amp;%; SfOÄ. SplvR-, NR**S(OfeR**,: NR^í©)PRrtR* és Sld^NR^R^ közéi egymástól függetlenül kiválasztó« 1,2 vagy 3 szubsztíluenssei; :Wqß háratélyík R** és azzal az N «ómmal együtt, amelyhez kapcsolód«^.#», 5·* ö- vagy 7-tagá heterocikloalkil-csoportot képeznek, amely adott esetben szuhsztltuálva van alkil, C5,j cikioaíkih 4-7 íagé heteroeikloalkil Cfc.|., aril és 5-6 tagú hcteroaril, €;.;, haíogénalkil, halogén, t.'N, OK"*', SR*\ €(( CiO)NRi6R:il\ 1.'{0}0RS\ OC(0)R,v7. (í€(0)NR‘'<,R,í<,f MR^Vk NR^'tOIR^, NR^CPINR'V'', NRa>C(ÜK>R!><\ dí NR''"iNR'·'R'", NÍ*rV; NRft')NR^,R'i<>, S>0)RiA. Su nNirV”. S<ÜU<ío NR SCOí-MÓ NR“>S(0}pRsi,Rd8 és SíO);.NR”“R*tt kívül egymástól ftlggelíenüí kiválasztod I. 2 vagy 3 szubsztítuenssd, ahol az említett ί.\(. alkil, 0, - dkíoalkil, 4-7 tagú hetetodkbalkíl, CM0 aril és 5-6 tagú heteruaril adott esetben sziibsztítuáíva van halogén. CN, OR;"!, SR* CíO)R1*, C(0)NR<6R‘te> C(0)0R“ 00(0)1^. OCíOJNR^, NK',ftC(01Riy's N R ' bC(0) N R1 h R<l'\ HRtftC(0}0R84, CpNR*6 ! NR'*!!*5*', NR^Cí ~NlP)NReSR'!\ S(0}RÍ,:\ S(OjNRfi<‘R!Í,!, SíO).Rbí\ NR^SiOijR* NR^SfOfcNR^R*· es StOX-NR^R* közöl egymástól függetlenül kiválasztod í. 2 vagy 3 szabsz Mue ássd; vagy: bármélyilí ReS Is R^azzal az m ateHímak:égyi«ti:amétyhéK kafesolóöhaíí,% 5-, 6- vagy 7-tagti bétsó3e!klö£dfel:i->esoptí!íöt képeznék, amely asíott Ç3.7 eiklóalkít, 4-7 «iga heterocikloalkll·, CVi„ aril, M tagú heteroarll, Cí<ő, hnlogéöáMk Pió§éh, €1¾ #1*, SR?* C(Ö)R!*\ CCONR^R*, aü)OR3\ <KV>)#, OeppR^lP, NRtÄRdfi, MR^ÖJR6! NR^GppR^R^ ΝΚΛ0(Ο)ΟΙ'Γ\ Cí^NR^NR^R*’, NRe>,C(': NR^INR^R*', S(0)RN\ SíO)NRs6Rdó, Stf^R1* MR'''<,S(ö)íRbíí, M#S(Oj3N#R® és SiOpR^ közöl egyinástéi Slggettenül kiválasztöít 1, | vagy 7 szuhaziitnensse!, ahol az említeti Cf.(i alkil, C;.7 dkioafkíi, 4-7 tag« heteroeíkloalkil, Cfr!C. aril és 5-6 tagú heteroarll adott esetben szdbsziitdáiva van halogén, C?C OR'*, SR?6, C(0)R*\ 0(CWR*R* C<Ö)QR*, 0C{0}R* OC<ÖpR*R* NR^R* NRl<,C{0)R"\ NR*Ct<»)NR‘ Rá , NlOVtí ))(>1ΓΑ ( (-NR^NR^R* ΝΚΌ l( NRe*hNRt(>R'iö, scape* s(o)Mrt^: nr^cöxpr^r* és sKp^NR.^46 mm, iuggetienöl kiválasztó« I, 2 vagy a szuhsztituensseí; yagy bámeiyik K1·5 és R® azzal az K aiöm}«| egyött, f% 6- vágy 7-tap hétgtociklűáifeS-csoportot képeznek, amely adott esetben szúthsztltaáiva vast C;.,s alkil. Cs..7 dkioaikii, 4-7 tagú hétéröcikióalkii, Ct!.l0 aríl. 54 tagó heteröaríl, C:.* halogénalktl, hsiögén, €N, OR*6, SR8*, C(0)R^ €íO)NRcí,R'!,:. CiO)ORS!>, 0C(0)Rtó, CXXÖWR'V*, NR^R*, NR^OR“, NRí4€(0)NRc<iR'tó, 'N,Re!lC(0)ORsi, í.t NR^INR^R’16, NR^Cf-NR^íNR^R^, SÍO}Rw, ‘>(0}NRsbR‘’4, S(0)pte. NR^SiO)^#, NiR<:>'S(0>j.NR""R!!" es SÍOj;-NRí:<:R;it' közül egymástól függetlenül kiválasztott 1, 2 vagy 3 szuhsziituenssef, abal az emiiíett Cj.* alkil. Cj.? clkloalkil, 4-7 Rigú heteatcikloalkíl, C^io aril és 5-6 tagú betettsarii adott esetben szabsz!boáivá van halogén, CK OR8', SR*4, 00)1^, €{0)N'R';<’Riif‘, C(0)OR\ OCCOJR^, 0C<0)NR^if, NR^R'1", NR^VtOáR^, ΝίΓ'CfORsR^R^, NR^CCOPR*6, C{- NR^INR14«^ NR^Ct;; NR^NR^R?*4, StO)R\ S{0)NR' RJ>, StO) Rl\ NR^SfOblO', NR^S(Q:)2NRi6R<fc és StOhNR^R^ közöl egjottásld iÜgptiénül kiVSlasztöSt :!, 2 vagy 3 szubsztltiinnssdj R*1, R'\ és W* mindegyikének jelentése egymástól föggeileoííl H, CM alkil, €Μ, ÖStó, SR*8, Μβ)^\ C(0)Ru\ S{0}>N.rf;R* és CCOjNR^R'* közöl van kiválasztva; R**, R1”, JP # Rrfi iömöé^ikének jéíéniésé: egymástól függetlenül M, C^» aikik Ci,4 hafegénalkil, alkenil és Cp, alkinü közül van yyâlasétyâj ahol az említett CM alkil, CV4 alkenil és €>„» aikinli adóit őseiben szubsztitoáiva van OH, CM, amino, halogén, C,.a alkíl, Cm alkotó, C(.4 alkiltio, C,..#lkiiammo, <.1ί(€..+ alkiljamino, C^., halogéoaikil és ßH baiogéoaíkoxi közöl egymástól függetlenül kiválasztott 1, 3 vágy 3 szubsztitoenssel, vagy kánod y ik 1C' t\; IC" azzal ni N atommal egy&amp;b 4», S*, é- vagy f*W$ß haiercíclkloaikü-ésöpöttékkéiiezöek, amely »doit esöíbéü áétibpítitíálya IPS tóti CM, amino, halogén, CWMk Í'i.4 alkoxi, Cu alkiltio* Cm äfkjlamihö, :<$'€)*. itjkiljamlnö, Cm tódógénaSkil és haipjgéítáÍRtSííl Ítösíiil égymástöl függetk-uü! kivalas/UM 1, 2 vagy 3 szabykiiÔfêïtSBéi; és R^mindegyikértek jelentése egymástól tóggéííenüi Π, Cy„ aíki! és CN közül van ki választva. :1: AzA, igénypbiszermii vegyidet ygp éhnek gyógyszetpttóifég elfogadható tója. ahol áj íé jelentése: M, Cm alksl, Cf;,!ö árílj €gte elkíoaikil, 540 tagú heteroarii, <1-10 tagú heteroeikloalkil, CMÖ öfÜ-C^ alkil, Cfos eiktoaikii-CM alkíl, fMiÖ tagú |*pr«iál)-Ci4 alkíl vagy ¢4-10: tap heterodkioalkíi)-4¾. alkik almi: az smlptí C^gtkíl, Cs.4* pi| Çpô ciktóaMl, 540 tagú pieman], 4-tö tagú keteroeilctóatki], Ο*«,, ari}-CM alkíl, e:ikioaiki:l-C;i.4 sikik,(5.40. tagfohetefoanlj-CM: alkil és <4-3Θ tagú: hetevoeikloalkilj-C^ alkíl mindegyike adod: esetben szabsztóyálva van. R^ ttæubsztpenssél; vagy p # jeleníése K, £:m alkíl, Cmö clklealfcik 440 tagú hetemeikloaifcil, C^ii3 aiibCM alkíl vagy CkÄ dklotókil-C,,, alkil; vagy ej Rf je lentése C m alkíl; vágy d) R:J jelentése metis.
  2. 3. Az h vap2> Sgéitypoat szerinti vegyöíet vagy ennek pögyszerészeíUeg elfogadható sója, ahol R\ R" Is R5 mindegyikének jelentése H.
  3. 4. Az 1-3. ipnypontök bármelyike szerinti vegyidet vagy ennek gyógyszefészetilőg elfogadható sója, ahol a) R\ R5, R6. R' és R* mindegyekének jelentése egymástól függetlenül íi, balogén, C,* alkil, Cw halüglnälkikCN és OR'*’ közöl van kiválasztva; vagy b) R4, Rs, R'*, R7 és R* mindepíkénp jelentése egymástól függetlenül ti, halogén és meíoxi közöl van kiválasztva; vagy c) mind R5, mind R7 jelentése metoxi és E:!, Ír és R* mindegyikének jelentése egymástól foggetienö! Ή és balogén: közöl van kiválasztva; vagy ál 1? jelentése hafogóo, Rs jelentése metótó, 1* jelentése M, R7 jelentés® metoxi és Is jelentése halóin.
  4. 5. Az ( -4. igénypontok batmelylke szerinti Végyöíet vagy ennek, gyögyszorészetiieg elfogadható sója, ahol aj X jelentése CR*5; vagy fe) X jelentése CU. 4 Az :1 # tgésypöíitok temelylke sxsriMi vegyötet vagy ennek gvőgvszstPszeiíieg elfogadható #Ja» aiitsl R!S jelentése H vagy SUOtagû beteroaril, aaîeiÿ aë4t esçlfocîn Ci,« alkllesopörttaí van saibs/igiiâlva. ?,.:êM· -1-4 igénypontod Mrinelylke szerinti vègyület vagy ennek gyögy&amp;^fésxetííeg eifopdhaío sója, ahol Rjelentése Cj.(. alkih amely adott esetben 4:«7 M0 helen>eikloaíM^eso(><>rttal: vatt stíni^on.iálva, amely 4-7 tagú heierodkioalkii morfolinil, píper&amp;zinil, pipérídtefts pirroíidmil, tetrahidtPlhtanii és azetídlnt! kßxftl van kíyélasxtygj és amely 4-7 tagé tetterocíkioalkil adott esetben bxuhs»l?uáiva van halogén, C,.„ aíkü, haiogénalkil, CN. <>R*\ t(OtRw, Οί,ϋΙΜΓ'l4\ < íUiORf'. OOiÜ)Rs\ NR-'R*' es NFCVtOm^ közöl egymástól ÍÖggetlenlH kiválassftott 1,2 vagy 3 szabs/umenssel, iivázXR igénypont szerinti vegyük!: vagy ónttek; ip^W^s^l^xilifópdhaíó: #Ó|% ameiyssk::|ilaj képlete
    Ha. V. A 8. igénypont szerinti vegyidet vágy ennek gyögyszerészetileg elfogadható sója, ahol R4 jelentése teslögén, Rs jelentése tmmL Rö jelëntésè Ü, halogén. H). A 1 vagy 9. igénypont szerinti vegyöfeí svagy estnek lyágyszerészetiteg elfogadható sója. ahol R';> jelentése Ο).* alkik Ü, A 8-íÖ. igénypontok Msinoiyike szpriót! vegyidet vagy ennek gyógyszerészeti leg elfogadható sója, ahol «’0 jeSestésó%f5 áiklteameiy adött esetben samsatítnálva van 4-7 tagú betétetiktoalkíl-esoportlal, amely 4-7 tagé heteroeiklôalkii msÄte, ptpemztesl, p|>#yinik plrrolidmil, tetrtindroforanil és azetidími közöl van kivé Iáitatva, és amely 4-7 tagé heteroeikloaSkil adott esetlxtn szrtesztituâlva van halogén, C-^ aikil, Ci.* haiogénalkil. CN, OíC\ C(0)RM. CtOlNR^XCy C(0)ÜRa5, 0C{0)RbSs NReV$ és NR**C(0)Rw közöl egymástól Ülggetienttl kiválasztott 1,1 vagy ? szubszfituenssei. 1:2. Az 4. igénypont szerinti veg> illet, amely a következők közöl van kiválasztva: 3-t3,5-DinteíiiXÍf'enil)-l-metsi-S-ií--metiÍ-lH-pirazol-4-i]k-Í,3>4!7-teirahidro-2n-pis*ó:ktf3V2,::5Jójpir!-dof4,3“d |pinmtdtn«2-on: -karbsxamid; 3-(2~K lèfkî .S-dí trxitoxi fenil)- J M[3Wi5iôJp8Mo[4,3^d’jpjnmidin-2Kin; í oi' jî ‘. ΙΓ ; 3 j^ïi t «í«f -I » 3 -ci j j > i r ïî ïî s d in- 2-on ; J42~K.i6F^3jS»dÎm«tôxifenil^:i-^ÎïïiS“(l‘m#n^il*p^*ôî»54î)v}ïâj:^?rtett^iidr6~2H~psn'o*: lo [3 %;2l::5 jpirí tíí>(4j 3 -d |p ír nil Idirt -2-oííj 3·>(2-Κ1όΓ'3,5-άΪ3«δΐ0Χΐΐβ&amp;1ϊ)-ί“«ΐΒίΙΐΐ3-0χθ"2,3(4 J^í:eSMite»iH^feo|ss|3· ,22$$|ρϊΗ4οί4,3« ••d)pHHnídm-8-karboniín(; PP',235,6 jpi)k(oj4,3-d|p}rimÍdÍH-2-on; 3-(3<5-4)ííncKíxiien!Í}-í~mettl^~(l>'medíp!pBridW^'tli'l>3,4J-^í#iÍd«?~2í33p!íTöÍo[3^22Sjö|piHdö{^Jv dlpífiniídiü-k-o«; 3-(33~Diniek)xjfi^i])“M?M3'ÎFÎïôÂ^osô'*:>3>4^ietiHhki}0-!H^pifiO!o[:3!i2':5,6jpinde[4I,3-ïd]pi' (»'»dir· S-kærboxamid; 3··(3.3·Οί metox Í fö«il)~8^p^MdroxisxetiÄ^:ldl}ka^öJ] j- î *mM-lo|3’,2’.' S,6 ;piri(k'f[4,3 -d ]p>ifi sït i dirs -3 - öí 3 ; 3 -(3.3- Din3et(>xífei3tl:J-8rfpdiMroxip)f!'OÍ3cípi-- í-íi)KarlKmlí}-1 ‘jtte«}- i ,3.4,7-tdU«hidrc>2H*pirro~ !of 3\2’: 5,6 jp ín' dci(4,3'd)pki 5tbdffi-3~ot):; 3-pp-í.(inseti;xí!knií.í Osncdl-H •[(4'-n)ôti!j>jpei'aziî)-i'll)kasbôïi)ij-(,3,4,7-(etraí'iídn>2]-l'p!)T0' 1(>f3',2>-S,6Jpsndoj4,3"dJpírini)dá)^-»öip j^p-'Kiór-.kS-<la)ív)tox)feí!Íl)>-Kvl •'dimBí!Í'2--oxö-2p:A?-íeííaíúdro- Î kkpif>oio[3i>2‘:3,d}pifiáo[<i>3>d}pk rim id ίΐΐ-íl-k arbox a n s k( , 3-p“-Kiór-3,3-dimetosilV!)l!}-N N (dúincfilP-oxo^P^J^rahldró^H^pl^tóP^^őlpMácI^* •'djpi)))'nidin-8"karh(;xai':)id; Î^Î-KâôroP'-diîïïëtoxifenil)-8-[(Spidixíxiazeiidi»·-!-113^^0)50)-014^(11^(^,4,7^1^1)(^0--2(3^1^0-k)[3\2k3>6)pir;dö[4>3-djpir!?))iálí5'2'0n; 3-(2-K l6!~3ï5-dimeîôxiPni(3”S''metil-8-x{p-medipippmxtî5-(-i1}kâTb0ô5|3-ipi4p-4;^)fkiîidmpH-p|î(;)-)(.)(3 ’ ; 3.6]pí ( idopj-dipblmid ())-2 -on ; N--Csk lopi'op(l-3-(2-duor-3,3-d(mB)0X!:fc )))1)--(--n5edí-'2--pxp-2,3>4>74«ö4ikPfó-fHíipírröi»>p!,2!:Sp3pif:(-di>i4,3'd]piri(!))dio-8-karboxarnid; 3--i2-F](!0r~3,5-di)«et0xifc)ii()-8-|(3'-ii:(d{^)kíaíísÍ:id(«-O5jpsíbppO))-ÍdííB5(}-l,3,4,7d®t(al)td(X5-2P-ptrF0- !oí.V.:?':3,6]pÍÍ'ido[4,3-d)psí'i)55íd!íí“2-oíí; ! •{[3-(2--Flüoí-3p'x!i)natí5xi%iií}'i-d:íeíl!)2-;öxo-2ppi7dstdiPdpv-lH-p)íT0(éÍ3'p’(5P}pkídö[4p-•d) psri-nidi n- (Fii lkaikon i 1 j pirrol id ())-3 -karbomiri! ; 3--( 2"Fl«<«--3,S--d(}««ioxifcRn)-{-nte|i^[(4-4n^PpiÄftv1*B)käiÄiil-i33^Hfe^rf#o»2S*p(*p-ío[3!,2':5,<>3pirkii>{4,3"d]p)fiinidm-2~on.; 3-(2-F!i!Oí'-(,3-dÍ!5:Cíoxifcr)í])-8-|C33Í5Íáíx>xip!per(díd--i-ii}körbóPÍ(3'd->{ne(:(OÍpí4s1óí6d;á!ddrö-2ÍÍ--pí(Tö“ ío{3,,2;:5,63pirido[4>3-d)pitimkiíri-2'paí • d jplil mid in -8-karbuxa?n id ; .^ipirimtdin-S-karbuxannd; vágy « feni említetlek SwmdyikÉtsk gydg«sim?^s^íií«g (di^aÄaf6si^m £3, Äz I. igénypom szerinti vegyüleg :a| a következők közül kiválasztva: ä“{äm^i!lf«0!'-3,5misneiDximni])-l-!«iSiii*^<te{mlfidi0^i|-p!r<}n-'4-ilVl>'?>4)7-!Vtr3hi<;irO'^fHntn> ktf3'p;:5t6|pirKlo|'4,3-dipiritnidiri-2~on; :3-(2 jö-ci ifi uur-3, ? ~d i nteto x i fe ni S)-f - '«éti í < 4-met ti pjpemKÍm1 -il)ka!bömi]~ t^J»4s^eímfxtdtms2M-p|í 'fep\2:'::3,63pirido[4i3-d3pirimidfn-2-on; 3-(2 J-diif nsr-3 m-dimetoxí feiülj-l-S-ímormiin^-MImíkmdi^^J^^^tfalidFo-Síí-pfín-íöf3::,2!:5/>|pindo|'4?3-d;]pífimidíö-2-öa; 3~(2m-díifuör-3íS-diöetöxifeil)“3-ti4,4KÍÍfi«ön>iper!di«-í-íifkaíböi«í]-l-«f:if"l -ipiiTöle[3f,2k5,éJpifídt»f4,3-á]pírímidm-'2-on;. vagy a feni említettek M«ngiyikáv#::^^^eetogíite§ elfogadható sója; Ψ80- b) a következők közöl kiválasztva: 3-(2>6~ϋίί1ηοΓ'3!5-άΐ^·δί0Χί^ί1)^^4^|1ί^ρ^^0^1“ΐΙ){ηβίΐ1||-'Ρ4·0β®1^3^ί7'ΐ®ΐί«Κίάί®^Η:-·ρΐί*0“ :lö[3!i,!2^5/íJpnido('4f3-d]pkiiniáih»2'^i;; ϊ3^,^ΐή«^5(§^^ί@χΙ^«}1^Ρ44^ίΙΙρΙ|ρδί«ζ&amp;“1·*Η5^^^Ν.4»;0ΐίΜ^4^·»ΜΑΙ*^0ίγ2Η·>|)>1ΐΐ®ί“ iiíP^kS^liniüdöid^-'dlpísmtdin-S-ínsi i öp’,2’: 5s^pirídí>f4 s3-d^píitnídf n-2-íhí; 342fS*áfíf«or-3p-d£mmöXiMsiSJ-k-[(!-eí!Ípiperkljri^-il)mé£ii|-!-metií-fppp-tetrakídim-2tftP!it'ö- inP^kS.SjpiridoHP-djplrtmidin^-öív; 3'-(2/vnjiifüör-3>S'-áiníetoxtr«i;l}-l-í)^etil-S-(niorfólin-'4-iimetií)-k3!4I7~tet:rahidro-2lf-pií'rO'' Ifepy’tS^ptrtitel^S^^pftisiÄ-S-oa; 3-(2,6-d if 1 «öf-3?S”dtiB®ö3xi fen i ll-S-ip-hl drexipfperid in-1 -4 I Jmeíií {-í-imeí i 1-1,3*4,7-íetrahídr ö®^im>* IpP’pkS^jpiridoldvS-djpiífmídift^'ön; 3-(2<6-4ΐί1«0^3ρ-4ίΐη8ί0ΧΪί4βίΙ|^-|(4ί#^:ΐ§00φίρδη0ΐη-1-ϊ^8ίΐΙ|-}-ίηδ®-3>3,4!?-·ί^1»0ΐ·0'2Β·-ρίΐΤ0- jo[3(2m5ö>jpiiido|4v3'djpisimidi!^2-or!; 3"(2,6-d ifi »oi-if.^-ditndvixiieniif-S-iCifd^difktotpipeTitltn· ! dOrnmif j-î-m&amp;di- 1,3,4,7-te!xaiifdm-2Hpitri>· ioP>235.6jpiridop,3-dJpiÄidin-2-<)m 3"(2df-dtfUtor-3f5-diroeiu%ifemi)-{-roeli}"8“(2-roorfoiin-4"HetilH>3A?~tetrakid«>~2H-pim>· .ioÍ3k23:5,6}pi{i«k)j4,3<íipiri>«ldití-2-c<n; 8-f2-az«íidist-1 -Htíf ií)-3 -(li.ij-difliior-J^-iiirmHOXäfenil}-1 -metil-1 ^^T-tetrahidro^H -plrroloili’^kS^lpi-(•)di>j4...>-d]pi.timidtxi-2<.sn; Mïj&amp;ÂÎutïp^S-dimeKiîùfglïÎîi^'KMil^-^^ k)f3'!2':5i>]p!rido|4,3-dipiritiJidiit-2-sax; 3-(¾ -<âÎî1ïÊôr-3,5-d smetöx ífet> m et i I - S -1 i-nun foHn -4 <Mprë^sil.)^ 1 ,-3^f4éiraifattÉSH-ï>îtl^ ki[33233,6]piridG|4,3-d}piri.nddin-2-on; S-[3-(4-€!k3epropí!pipera^in- !-il)píxipi;)-3-(2.&amp;-dínuor'''i,5'dtníeíoxiíöni])-1 -metii-i.3.4,7-tefrahkirei-2I4-~píttOks[332k5/i|pirido(4(3-d}píriiniü»v-3--oru J^2?6-di8i^p-3,S-d«»etóxífc«il>^-í(4-eíi]p»í*tas3Jt»-:l«U^i:ari>onll)4'íO)ettí<‘-l>3i4>?4etFahidro^2H-‘piito- löP'y2!:5?6]pirtdöP,3“d]pítHSddi«-2-öní; 3*(2/>'á!ÍTuör~3)5-'dtnietoxife«(Í)4--{f(3R,5S}-3,5~diffieíilpipenizm-l-iíJkafboíi!Í)-'i'mMiS-i,3:,4,7- ~tiítrahíc5ro-2H-pír{>ök>[3!>2<:5>6jpiríd<>f4;3-d]píHníii4lrí-'í-on: vagy a fent smbietek bärmelyskeitels jyögy^^szeídgg sífögadhsíó sója; vagy eV a köysike^ök köapl feíválassava: 342,e~dií1ifi>r-3>5-dtaetoxí&amp;«iS}''] dí>j4,3-d|piri«o idői-2-on; 3-<:2,6-cí {tKtor - 3 »5 “dimetöxiífej iil)~ í -et t í-8-[(4-iíí eí í Ip t peraziíi^ I"- í límetiJJ-l t3p;7-tstt-aliaíf»s2H*pírRí-k)(33235.ó]pirido[4 J~d]pinniidm-2~on; 3-(2,ó”diíí«or'3p“dÍ£{íeípXÍted}-í-'etíl-8dW-ed^PPeí'37>d''l'iS)ínMní"lí3p;t?'4eÍrahÍdíö-2H-p!rt:ö* k)P32kS56]píridoí4,3-d]pirirnidin-2-ön; ioj 332’: 5,6Jpii kkt[4.,3-dJpirinikiki-2 -on ; ... 3 -(23Í-dflo<«r-'3,$-diníekxxífeidl)--8--í[4424Hdröxiatíf)pjpsra?in·' I-iljmeidj-l -metíi-1 .,;3,4,74eti«fhiäö3* .r2:tI*pttToki[;r/235.6]psrp^iï»â3p:Mteyfe2'^|ii 3-(4- ; [3-(2 A4-dOi»or-3,5-dÍRietpxiieníl)-'I-mtdik2^ö-2,3,427''ietrahídrO'ífkpím>fö[3V2k$i6Jp#idöf4i3·· :pJpirii£ndin-S-il)ineü])pipera2in-ld!jpröpännifVii; (-{[SdS.ó-diduor-S^-díníőípx^foííJ-NneÍü-S^oss-SjSp^deífíaiHdFo-lH-plrroiop'^'^jóJpiridopP- ¥d|pirlnndin-S-tl|nie(i])piperidine-4~ka)3íOipmí; <3S}' i -{P-{2,6-ddluor-3.5 -ilhnctwfrnilH ~med J-2-oxo42,3,4 J-te{Äd^ö4:H^m*iiöPi;2kSÄM» .do(4,3-d|piriTttidhi--8--íS|nietií}pimdidui-3-k;irbonifriU ;>-í.?.,6-dií!uot'-3,3-difnek)\dkrnS}'!-ineiÍ!-S-| j( í'meíi{piptn4ítín-4-:í:iJammö)tpedi}-i>3!4i;7“teí:mhid:í’ö-2l3-:jdrröki[33235,6jpirido!4,3-djpi>midin~2-on; 3-(.2,6-di{luof-3,5«dímekJxi{'eniíV I -nunii-S- {l(3S)*Mraldd»tikap-3-(l8Pi}pöJöt«ii1:}:-*I:y3;d*7-isdvaiddi‘ö-42iï-pirro!oj3!,2':3,ôjpindot‘k3-dlpirimjdin-2-on, 3^2 3)-ϋίΠ!!ο·Γ-.k?-dknvU)>: d^n il!-· ! -πΐ<ΐί 1--8-3(( jR)-U'ü^(hKÍroi\íríin~3-ijamínöjmetií}'1,3,3 //-tetrahidro->2líd-pirroío[3',2':3.v'>|piriiJo(4.3-d(piiiot!dífi-'2-on; 3--(:36-dí Πικη·--3 v3--dsmeíoxíl%ndJ-8-(:í:® Ipdda^i-1-iteötií)-1 ~nie(ib:l 3P,7*kalHdfö-2:I4-pi»'e·-ÍOp’^’^sbjpiridopkk-dlpitimidíH-k-oiv;: ioj.332' :53>]pkiiio(43-djpiriïnidiR-2-<yri; S^id-diduö^i^-dkiiptexifeniö-l-inietM^-fff'jPetd-lH'piraxo^dlJm^iJj-i^jp-ietnshtdrtt-äii^krö- {o(33235>6|pitkioid,3-djpinroidm-2--oxf; 3-(2,6-din«ot-3J5-diifiek)xí:to(!^l,tHe(£M-(2-piridsn-2-}!eti1>{,3!4,7-totfahidfo-2H-pirroJöP',235í6]pín- do(4,3-djpirii»idi»-2-t.>»; 3-(2-^16^6-0¾¾^ ,5>:díme íox d en jlJ*|‘eti|SÏ-{moriôî íb-4^ dnveíib ί>||^4 ídircí^iH^ö^öí- ÍDpU’:5'ö'Ípirido(4,:í-d]pin'mídíiv?.“Ofí; io!3(2^5,6jptridi)(41.Vd]pir;ïnÂ4-iHU 3-(2dï-diî)vii:ir-3,5-diir}etOKÎienii)'8“[2-(3-fîuoÂÂW:-d5Mi|-i'-metii4|j3ï4j4gti®Wdm-2H<pn-o·-;|ρ ( 332’ :5,6] p ii'ido ( 4,3 -d ! pin f n idm-2-o«; ίο{ 33235.6 jptndoi4,3~d]pirifnidiiv34d©j :^i2,6-iddiiDr^!5”dinwtoxíÍSi5l^lrp-hidmxÍedi;J-S"p>4ís}ööds-4di'edl)vÍppp-)«ír^dm-2!Í^írö- loÍ3(3254>jpiridoj4!3'd|pírimidin-2-öR· :>i2,6-(iif!v:or-3,5-dinwtoxi;&amp;®i)-Í-:p>-fluorÉssÍÍ}-8-(íHörfeHii-4-ílínetd3'd,3,4s2-teírahídfö-2H“piii®- Ki[32225,n|p;rido;d,3'd|piri)i!!din-2-oft; 3-(2x>-dinüord)5-dírnetoxifcidj)-84P^íSippe^®-'3”^|í«sd1Í-l-(2-iüöi'ífö8Íl)-l,3,417-fóffdhidn>2í^ •»pírro1o[3\2< 5,ó|pKÍdof4t3 - ti} p i ri îït í <ïi t -2í-oí ΐ : i-cikiohttíis-3-( 2,6-diÛ«or-3,5-dîmeioxifemi}-S?(mpd«iÏ8~4-t|î^iÎ|i~ lo{ V,1 ‘ísöIPi* *‘ i! 1 ! 4,3 -d]pirimidtn-2-οπ: l-ctit hindii-3 (2,6“dinuoT-3t5-dinïeiôxifefiî|^8-p3fî}OFMis-4-iietii^iJ,4;2dÂ^ddiô^H-pte-:lf»P'>2':5>6]pirido{4,3-d|pirímidÍJv2-on; 3“(2,6-dtíluo!'~3,5-diinetoxíiet)iii'8-(niofföÍin-4d:Íöíed|^|>|TOpÍ3i,3:,4:,?4gfmhldíO>-2íí-pirF6~ k>[33233,<>jptr!do(4,3-d|pÍ!'ÍTnidiíi'2ots; 3-í2,6-diiiui>t· :k5-(iiinekíxii^íi)d”etíi4:d2^fíkíríöÍis-4-ifed(H>3,4,7-tetndddrö-2H-f ií'röiöE3’>2,:J,6]piti·' do[-i ,3-d]pirítnidin--2 -on; •)o[3',2<:5,6jpjridof4,3'djpirimíd»n-2íö^· i -cíkiopropt i-3-( 2 ,P-d iíluor^3 ^‘54<ííí«^fpí£Ífé»iÍ -sp«ÍiIpíp©raKíri-· 3 i »3 j4>7''tsíi‘ab idro-:2Íí~pir' :rok>[3,,2,:5,6|pittdoi4J-dJ;>irimídi»-2-<m; l-cikhpmpií- > (3.ti diH!!or-3.S-dirneîoxsr«îîd)-8-[t4'Ctdpipenuin~!-d}ffîeïi]|-Î,k'i.d'tcifahidro .?H-p:ms· ii'>|3'>?,'5^!piiidit[4, ' «l}ptft'.n>tli«-2“On; 3d2,6-diiluor-3,5-dimetox?í^si>]-P4-topr|epi|3g-(:p3öi-|blm-44kTíeííi)-},3>4,?d§P^Mdí'0-2l4*pirro- iop3235,6]pindoj4,;}-djpinmidh-2-oti; 3-(2,6^itluor-3,5-dimdoxjrmi0*H4-ftödffeß||fe^|(4^Ä|>|i3!«^lö4:4|j^d|-4,3?4^4te(^iite%2Mk -ptnoio!33 225,6 jptridoU,3-d {pirinndtn-2-on; 3-(256--t?tiiui>r-3,5:-cijmi;iox; fon 10- i -(4 - îî u« ΐ"ίΐ?ϊ>ΐ! :^8- [(4-S ί ΐ I p Ϊ i ÎJîïïiîtli ^ 1,3,4, ît^ti í íidrö'\2 M>> *p«T<íío|3>,2,:5,61ptrído(4>3-<ijptrinridie-2-on; 3-(2,6“tííni5or-3,5~í.Un^ei4>xLfcníi>-í~^2,3-<iií3po itííef ti i3~S -((¾ ^ îïï et íl|SÍ 1 »1Π tPöt: ïî 1,3 .-ψ ^ 7 - teirah itiro - "2i{“pir>OkH3(2,:53>Spititioj43-d]pitimidin-2rvn’( 3-(2,6^in««r-34s^~dimetosira)il)-t-(22i-diflw#teö48-[(i4;<«il1pipfö(»Äi-.l>ii^d:|41:J|,4,7:“ileiöBMdro- -2H-pinuio[3<,2(:53>]p!fiti«[4>3-d|f)snirtí<iÍTi-3-í>in 3i(2sd-dii1t}or-3,5'diiïîetoxiitfdi.)”8H<»of}biiti4-dâ«Bdi)-i-plrid!n4-ii-î>3!4i2-t8tt!idiidi,o-2Mipiïïô· iöj 33235,6 jpiíídt>í4,3-d)pírstnidín--2-i>iú j$j!6p\?*:$,6 ipirido(4,J'd jpirimíd m-2*on; 3 (2.6- difluor-3,5-dimetokífeml s- I444^eWÍ«ám4lí>-p5Fíö-bp1,^ 3,6}piricki|4,3-d]pifimídía-2-on. 3 •(2>6»dilluor-3<5 -dímcioxiíenn )-1 í -11^1:111- 5,3,4,7-$efraMdro-2H* 'P«'rt!lo[3‘,2',:5j6]p)ti(b|,4,3-d]pitimidúí"2“On; 3-(2..6"C}ífliior--3í5-díme{oxjfenl}.)-!-(--nuorrer»H)'8-i'2-(4-etíípÍper8zm-}-ii)eíil!-b3,4.?-ieiridt}dn>-?.H-~pd:r«lo[332':3,6'jpÍ! idoj 4.3 'd]pirimklifí-2-on; 342.6-dinuor- 3.:kdÍTti«íDíiifejíll)-í :li{âiî>*2H-pirrol(>{3'>2,:5.6jp«rido[4.3-djpir!mi(liii-2“On; 3 '(3.^-di fluor-3,5 -tlmíctox i IV« il >-1 *( i --ϊιϊ^ΙΙ,- 1 -35d-pin-«íof V.2^5.6|piridi)[-k:kdip!rimklin -2-oîî; 3-(2.6«dinu<M,«3,5-dh«<ftosjreBjl)-8-i(4-n>et5!p^ßf^i44Qmft)l:|4.<J*metiMH-pira2<>l'4-tl>.|>3.4J7- 4«í»W4fo*2H'pjTS'-ó!ol3,>2,:5,6jpirido[4>3-d]pírimid|(s4|-i«s?:: J«.(2«6'diööOf4<3^lmetoxiifeRil)-8-f(4-eiilpjp^}ö44l5mi6tH^14^Ä*^lW^^(N*Wpl:«lsl^ 4«ïf aÍTÍdf64líí^5Ín'oio[3 ',2': 5,6] piridof.4 ,3 -d]píri m iám-2-οΐΚ 1''IP~(2b'4dHiot^3.5-dítneíoxi?enilhS-n5edi-2~öso-'2í3!4!7~£8pabl^4£bpin'oio}á,.2t:5>6]pbidoj'4.3·' -tíj p irím i tîi η ~ 8 ^ i Í If « <ί ΐ i ΐ} a sæî id Ιϊΐίΐ >3 -kar b öíí4; ri I; |3iÄ }- :i IP -(2 ,fî -d i fiuoro. 5 -ds® eîôXïfô« í b- i-m^ii-4>-öxö«24,ds24e{bki#^ 5 H-ptnrotof 3bP Sb jpiri-(Íöf4.3-d]píf :int}diíV-^iÍ!:Jp)&amp;u4}pjtröSídiíV'3-kari>öií{pik .3 -< 3} í>~ d ! íl U í>r '3,5- d ImöítJKÍ Γόίΐί l(í- 3 - Ô tjófaxetííSí n - í - î I >e íí Î j- í ^<2 í - rpíjtoSo{'3^22Sk^|píí3do(4.rv'd|piíd«H#ift>2-'ön· 3-{2,6-diiluot''3, >-dh«Êfôxi feísílV ! ^id^SölbÄo^aB-päf«- Iö^:;2':5.6]piridí>(4,3-<Hpírítt«din-2'On; .kP2,d-di(ka>f''-3,5''dimefoxsbnil}-l-'(3“dässrfeni0-§-(möfk5iin-4-dikPid;M,3;4>?4ett®byfo^2B->ptow? ít)(3'.2':5;6ipírldop t3-djpirmiidin-2-iin; 3'·!2^4ί^«0Γ-3,3'4«ηδί:0Χ!ί0πί!}-1~(3”Ι1ί®Γί«ηί])'8-[ί4-^6ί1ρ|^·820ϊ':ί-ίϊ^ϊ^ΐ0)-:ΐ4>4>2-ί»ΐχΐΐ(ΐΡΓο-2]4-- ^hTolop\22.V4jpindo(4.34'jpinmidk^2~on; 3-(2,6'-diftöor-3p-d«»g(:6xiií6il:)-l ~(341i®fï«î;tl)“8-[(4seÎïbipf8æb-!-íl4ínedl4 J,4 J-Jéífdddkí^H' .pirruío{3^2254dpáidoSd.3'd'jpidmidí«-2-'on; 342,6”dif1iK>f-3,5'diî8ôd:>>:M!nil)-:l^îidSfP-<5Xi>ptttdlr^4(2H)-ii)»ætii]- !,3,4,'7--teíí-ab.ídTO--2í{~piiTo·· l<5(:V 2354(lpíridupP -d|psrimídin--2·-«:); 3-(2,6'didiK)r-434tb6iö4^f«l>!-«dkÍÍ^|(pffldb-3-ibxi)mét!Í}-!s3.4.?-istrahídro-2H-p5rro- kd.3'-235j'(|psrid<d.3»3-djpirÍtxiídíá--2-o:í; 3'(2.6-dinu()r-3Y5--dij?ied>xifóidlvl^(24ddroxiet!Í>~8dmorfoim4-ílbeiÍ)-'Í(3<44-töÍphídi>sí^2fÍ-pinp- ;jo[:V,2,:.1.6Jj:di1d<i(4y3-d|pifimidÍTí-2-őPí 3-(2,6-<n Πικ5Γ~3.5-diniétoxi fèôill-· I-(2p-dpaö!4bíÍMdp-mófibÍÍ84kÜptií)-ip>4>7-ted'8hympH-f bt»-lö( 3‘. 2’: :46ipirkäo|4.3--d)p!fiinid!!'.-'2'0«; 3 (2.6 diiluör-S.S-dimetoxífedd"í-pp-dp8effbîil3-8"p-(4-oiePpipp}^dïii-i ./^g-íptr«>b{3\2,:5»6{pirid^^^M«ái<iin-;t4öiá§; -2n-pjfmio}3k225.6jpirkloj'4,3-djpirimidin~2'<:!», U>{ 3%2' : 5,6||;> i r Idoj 4 ,;>~d jpir s í n i d I n-2 -on ; 3^2>6-dsiK«vO,5“dimd«xi{ênin-!-(d'nii#:deîïii)?^-[2*{4^siiîpip0mdn^td:Ofetij|^i.»3»4i:?;‘tetfah5d5:O'2l:I·' gdmdnP'.d'': -4> |pirido[4,3”d Ipirhmdin -2-un; lp:|íVi2k5,6jpiridö[43*djpírinddin-2-ön; «pitén loj 5’,2::5id]pii'ido[4,3”djpiriinidifi-2-0n; H2.6"difl«i>r-3,5-dimetoxlfenil)* * ί -pirroio[3,>2,:5s63piritiol4)3Mdjpirim}din-2-on; ! - {2-Γ342,6-diiluor-3,5-dímeSoxiíenü >- ! 'eui-2-ox«-2.3,4,7-teirahidro- i H-pirrulo[.V,2,.d1i)]p}rîdof4, >-"d]piriníKhri-ÍPil jetii} axetidine~3~karbonitrii; 5 ( \o •\d«öP‘3p‘-d4®etosÍÍdpiÍ^í-«ííPS4^xP-^4öfazetídíP“il^i|ey3J-í J:í4!^íbi;pliidFöPH'pí«-olo[3!!21 :S,6j:'P uiojd,3 d]puimidííK2~on; 3 4 2>6-ddi«:ör*3,3-di metöx ifsn i i}-1-(2 - i1:tíareíd3-8^(:ffiörfb!m-4^iíí»0iil)" ti ^-pímldditp-'S ll^pifW- lp|3'p23,d]pÍHdt)[4d^dÍpir!níidin-2~ön; és 3-(2,6'-dÍllviös^3P”diínőí:osifenii)~ld2'i1:uarsíít|^8~|P-inetdpipei'aKÍi^ii”il)íííőtil]~i ,.3,4,7-teíra|íí<á®&amp;«ffi-· -phTuk>[32225><'>jpiridoS.4.3'djpi(in!kiif!'2-un; vagy à leni astdief tek bármely ikdnék gvó^-sxeíbsxetifcg dSfegadbaté sdjáv
  5. 14. At '%... igénypont.....saetiníi vegyidet, ànaïiÿ a 3'p,d“dtní)or-3sS4lteTOsifend)^í^sÍ"g^naSfis3ín"4^ -lídsítííH j3pt>?4ett,aliideö^233^pím>ií43k223;d|piridöPs3“d|pifíisddiP-2-pri vagy ennek gÿPgÿsaerésâstïieg siiogadimié sója. í 5. Az í> igénypont szerinti vagyaiét, aroeiy a 3-(2,6-diniH)r-3.,5-dimetoxiiënd}-i*«!Ji-8-(mori'oiin-‘t-4;íÍiitíetfí1f^Í:i3y4^7“tea^ííiát»*2H-pirrolpt3%2,:§«Ö3píí^ífe>^i3^^^öStti^lfei~S'«o*Éi íd.Aa I, igényptmt szerinti vegyidet, am#^:&amp;.:34i^'tS«öt^3,IAMtoxí^íip8“|(4»«i%íprasdR“-í* 4Í|fe«!Ö;iÍ-Í^stii>-í3«4j4«tmhj!Í^*2Br|ííiT0top^^!g3jpMád|4^^|pfe;ÍmlŐ^2*en vagy ennek gypgysze-· tis^tdeg eilpgadhaté spa.
    11, Ak L igénypont sgsríníi vegyidet, amely a íd. Az i. igénypont szerinti vegyidet, amely a 3-(246-diÍlüor-3,5-d:ÍHiet<)xifet^il)-i-ixtetil-8-(íní:»'föiín-4· 4imeiíi}»i s3/i:>?4éim}iidío»2ÍÍ-'pim>!of 3*,22 S,d jpiridöp J-d}ptftóíd!n^2Aín vagy ennék gydpfszerészeiíieg elibgsdast&amp;sbja. iO, A/ i iecnjpnnt sa'! inti vegyidéi, amely a :3H^iëw.iâi'fiiiiar-3^-diïmeioitiiifièfâîïj-Î-metiί^ίΐή?^^ 1.3^î^''tcitubùltoOI-î'ï>lm»loJ3-lT-5,6jpirido[-4!.3^|piÎl*a-|iâï8î'a!«Oô,..
  6. 20, Az i. igénypont szerinjU vegyatet, amely a <l{elil)«l434447'tetrahidf«-2U-i>»TOloi.T,2,:5%6}pmiio|4>3-<!jpiriK«<iía:r2-ö»: vagy ennek: gyögysxerészettleg elfogadható sój ÄI.
  7. 21, Az !. igénypont szerinti vegyidet. amely a S-^Ö-ditlui^-^y.dfcndöÄ^^ :4|gjtjl J-M A^-iettahidr«· 21 l-pirroloi 3',2*: \6 Ipirido^-dipirinridin-^-on.
  8. 22, Gyógyszerkészítmény, amely tartalmaz (a) egy. az M3, Igénypontok inbmelyike szerinti vegyöletet vagy ennek gyógyszerészetüeg elfogadható Sióját és legalább egy gyógyszerészei Heg el fogadható hordozói, vagy (h.) egy, a H„ 16., 18. vagy 20. igénypontok bármelyike: szerinti vegyöletet vágy ennek •;jgyógyS2erészetileg ciftigudhatő sóját és legalább egy·· gyógyszerészeti leg éíibgádkató berdozot· vagy <c) egy, a 13., 17., ló. vagy 21, igénypontok bármelyiké! szerinti vepalefét M legalább égy 2.3. Kijárás egy SGIR enzim gáíiásfeái^ worn ériotkezteíjilk ta) egy, az 1-13. igénypontok bármelyike szerinti vegyttletette) vagy ennek gyógyszerészeiileg elfogadható sójával: vagy ib) egy, a 14,, 16,, 18, vagy 20. igénypontok feártnélyike szeÄi vegpfeiepoi vap ennek gyógyszerészeti leg eitbgedhötó s||ával; vagy se} egy, a 15., 17., ló. vagy 21. igénypontok bármelyike szerinti vcgyöletettel. :-M. Az. 1-13., 14., 16., 18. vagy :2Ő. igénypontok bártnelyike szerinti vegyidet vagy ennek |íy6gys»zcrósafsetileg kezelésében törlépő alkalmazásra: sí tak; vagy b) rák, ahol az említeti; rák hólyagták, emlőrák, mébnyakrák, yssiag-végbéirálí, méknyáíkaliirtyarlks gyomorrá!*, lejen és nyakon jelentkező rák, veserák, tnájt#, tüdőrák, petefészekrák, prosztatarák, nyetöcsMk, epehólyagrák, hasnyálmirigyrák, paízsnuriprák, bÖríik, îëpfeémia, míeloma multiplex, krónikus iimíbtikus limloma, felnőttkori Ί-sejtés;leukemia, B^MlkrtÄ^Äöt*»Mögé» leukémia, ttodgkin vagy nub-Hodgkin limloma, Waldenstrom l^Äfjpü itafétlPk JSÉ.ett iimfőma, gSIöbiásztémáv melanóma és rabdoszarkoma kö,ml van kiváiasziva.
  9. 25. Az 1-1.3-, 14., ifi., 18 vagy 20. Igénypontok bármelyike szerinti vegyidet vagy érmék gyögyszerészetiieg elfogadható sója a kővetkezők kezelésében ttirténö atfeálídírótsrat a) mieíoproliferativ tvndeilenesseg: vagy b) mieloprolileratív rendellenesseg, ahol az említeti vera, ésszcmdálk, ttombodtémia és printer anelofibrózis közűi vart kiválasztva. 'Μ.·&amp;ζ: Ι-d!., :Μ,, :IS.,: 38:. vagy 2fti· igénypontok: baroselyiike «ζ«Ηηϊί yégyüiet vagy essek gyogp^rés?et!iîeg alSsgadkStS s&amp;síi aikôvejkexSk: kcieiésèbé» fôNIîtô aikâlmgzâsm: a) csssîvâZî vagy lissärseits rendélloüéaság; vagy bl csontváz vagy kondrocita rendellenesség, áhöl 8¾ eíslüeti csontváz vagy köss|meita rendellenesség aelfjndroplázía, hipochondroplázla, törpeség, tanatofór diszplázta (Tl>), Apen tünetcsoport, Crouzon ItssfösspOiíg Jackson-Weiss tiinetesopors, Benre-Stevetison bor girádo innetesöpori, FföÄr tünetcsoport es köpöüpössZécsóntosodás tünetcsoport hözíb vas kiválasztva». ΊΊ. Az 1-13., 14, i6„ 18. vagy·' Ä igénypontok báMelylke sxeristi vegyület vagy essek gyégyszerészetileg clfogadható sója a következők-kezdésében történi alkalmazásra: ajhípofoszfatétnia rendellenesség; vagy b) hipoíoszíatémia rendellenesség., ahol az említeti hipofoszlàtèroia rendellenesség X-kapcsolódó hipofoszíatéiniás angolkór, aoioszontáhs reesssziv hípöfbszfStsimiás angolkbr és áütöszotnáijs domináns hipofoszíatéiniás angolkór vagy tumor-Indtskálta oSZteibnialacKi. 28, A 15., 17,, 19. vagy 21. igih$$Ä a kővetkezők kezelésében töttétti alkalmazásra; a) rák: vagy b) rák, ahol az «miket! rák hblyagrák, emlőrák. méboyakrák, vasíag-végbélrák, mélioyáikshártyafák, gyomorfák. fejen és nyakon jelentkező ták, veserák, májrák, tüdőrák, peíefószskrák, proszttüarák, nyéíöosirák, epehólyagiák, hasnyálmirigyrák, pajzstningyrák, bőrrák, leukémia, midonui multiplex, krósikos limfbtikns lint fúrna. felsőnkön Ί-sejtes leukémia, B-sejtes iimföma, akut ntíelogés leukémia, Hodgkin vagy sösdlodgliís limloma, Waldenstrom makroglobn linóm ia, szárössejtes iimföma, Burkett Iimföma, glioblasztóísay:isbÍastása és rsbduszarkóma közül van kiválasztva. 29. A 15., í ? . 19. vagy 23, igénypontok bármelyike szerinti vegyidéi a következők kezelésébeníöfiéhö a ikoirnazásra: a) rnieloprol·. feral tv rendellenesség; vagy b) mieloproliferatív rendellenesség, «hol az említett mieSoprolllamtiy rendellenesség poiicjs2tibüÍá:W% esszenciális tronthocitémia és primer mielofibrözis közöl van kiválasztva. 3U À 15., 1?.. 19, vagy 21. igémpontokbtümclxthe szerinti vegyüld a kővetkezők kezelésében történő alkalmazásra a) csontváz: vagy kondrodta rétidéi lenes,ség; vagy b) csontváz vagy kottdrociia rendellenesség, ahol az emliiett esontyéz vágy :&amp;Oft#pe4li:-t«sádallé8í$S^ég achrondroplázla, hipochoridroplázia, törpeség, íanatoför dtszpfázla (föl Apért tüneíesöport, Croszoü tünetcsoport, Jackson-Weiss tünetcsoport, Beate-Stevenson bőt gicácío intsetesoporp Pfeif Jetii tünetcsoport és koponyaösszeesosíüsndás tünetcsoport közül van kiválasztva. 3). Λ 15 . :7., vagy 21, igdoypaomk bármelyike szerinti: vegyidet: a kóveíkezök kezelésében törtöiö alkalmazásra a) hlpoi'ua/faïéîHia rendellenesség; vagy h) hipyfcszlaléntia rendellenesség, ahol az esüftetk hspofoszfaíém® resídslleaesság X-kapesoíódö hipofosztáíémíás angolkór, aukisaomálts recesszív hipofoszfatömias angolkór és. antoszoxnális domináns hipöf őszi alcirt íás angolkór vagy sumor-indukálta öszieronmlada.
HUE13783125A 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok HUE031916T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261659245P 2012-06-13 2012-06-13
US201261691463P 2012-08-21 2012-08-21
US201261740012P 2012-12-20 2012-12-20
US201361774841P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
HUE031916T2 true HUE031916T2 (hu) 2017-08-28

Family

ID=49486650

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE16203866A HUE042374T2 (hu) 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
HUE18198112A HUE052195T2 (hu) 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
HUE13783125A HUE031916T2 (hu) 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
HUS2100035C HUS2100035I1 (hu) 2012-06-13 2021-09-09 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE16203866A HUE042374T2 (hu) 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
HUE18198112A HUE052195T2 (hu) 2012-06-13 2013-06-12 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2100035C HUS2100035I1 (hu) 2012-06-13 2021-09-09 Szubsztituált triciklusos vegyületek mint FGFR inhibitorok

Country Status (39)

Country Link
US (6) US9611267B2 (hu)
EP (5) EP3495367B1 (hu)
JP (7) JP6301321B2 (hu)
KR (3) KR102140426B1 (hu)
CN (3) CN107383009B (hu)
AR (1) AR091424A1 (hu)
AU (5) AU2013287176C1 (hu)
BR (1) BR112014030812B1 (hu)
CA (2) CA3149881A1 (hu)
CL (2) CL2014003355A1 (hu)
CO (1) CO7240375A2 (hu)
CY (4) CY1118744T1 (hu)
DK (3) DK3176170T3 (hu)
EA (1) EA036592B1 (hu)
EC (1) ECSP22091792A (hu)
ES (4) ES2832497T3 (hu)
HK (1) HK1212326A1 (hu)
HR (3) HRP20170430T1 (hu)
HU (4) HUE042374T2 (hu)
IL (5) IL289834B2 (hu)
LT (4) LT2861595T (hu)
LU (1) LUC00222I2 (hu)
ME (2) ME03300B (hu)
MX (3) MX359293B (hu)
MY (2) MY171375A (hu)
NL (1) NL301131I2 (hu)
NO (1) NO2021034I1 (hu)
NZ (3) NZ743274A (hu)
PE (2) PE20190736A1 (hu)
PH (2) PH12019502809B1 (hu)
PL (3) PL3495367T3 (hu)
PT (3) PT2861595T (hu)
RS (3) RS55908B1 (hu)
SG (2) SG10201610416TA (hu)
SI (3) SI3495367T1 (hu)
SM (3) SMT202000673T1 (hu)
TW (3) TWI706953B (hu)
UA (2) UA117347C2 (hu)
WO (1) WO2014007951A2 (hu)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
KR20150023373A (ko) 2012-06-13 2015-03-05 에프. 호프만-라 로슈 아게 신규한 다이아자스피로사이클로알칸 및 아자스피로사이클로알칸
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AU2013322838B2 (en) 2012-09-25 2018-02-01 F. Hoffmann-La Roche Ag New bicyclic derivatives
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CA3130452C (en) 2013-04-19 2023-10-31 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
PL3105218T3 (pl) * 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
SG11201607845RA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
TW201618772A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Btk抑制劑、pi3k抑制劑、jak-2抑制劑及/或bcl-2抑制劑之治療組合物
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016027781A1 (ja) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
US9255096B1 (en) 2014-10-07 2016-02-09 Allergan, Inc. Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019098040A1 (ja) 2017-11-17 2019-05-23 Dic株式会社 重合性化合物、並びにそれを使用した液晶組成物及び液晶表示素子
CN111770909B (zh) 2018-03-01 2024-01-30 Dic株式会社 聚合性化合物以及使用其的液晶组合物和液晶显示元件
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
AU2019262579B2 (en) * 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
CN112867493A (zh) * 2018-10-16 2021-05-28 达纳-法伯癌症研究所有限公司 野生型和突变型lrrk2的氮杂吲哚抑制剂
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN109939110A (zh) * 2019-05-08 2019-06-28 湖南中医药大学 药根碱在制备抗血栓药物中的应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114174272B (zh) * 2019-08-08 2023-05-12 漳州片仔癀药业股份有限公司 吡嗪-2(1h)-酮类化合物的制备方法
US11603366B2 (en) 2019-08-08 2023-03-14 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof
KR20220047810A (ko) * 2019-08-15 2022-04-19 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CA3162010A1 (en) * 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Jak2 v617f阻害剤としての三環式尿素化合物
WO2022193227A1 (en) * 2021-03-18 2022-09-22 Nutshell Biotech (Shanghai) Co., Ltd. Fused ring compounds as inhibitors of fgfr tyrosine kinases
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
KR20240122783A (ko) 2021-11-22 2024-08-13 인사이트 코포레이션 Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
WO2023195018A1 (en) * 2022-04-05 2023-10-12 Msn Laboratories Private Limited, R&D Center Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US11884667B1 (en) 2023-07-13 2024-01-30 King Faisal University Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US11897883B1 (en) 2023-09-01 2024-02-13 King Faisal University Pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891377B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11866437B1 (en) 2023-09-15 2024-01-09 King Faisal University 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (813)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (hu)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (de) 1971-11-16 1973-05-24 Bayer Ag Pyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
US3984021A (en) 1972-09-11 1976-10-05 Uhlig Gerhardt E Safety closure container
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (hu) 1974-06-19 1976-06-25
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (fr) 1978-06-13 1980-01-11 Chernikhov Alexei Polymeres heterocycliques thermostables et leurs procedes de preparation
CH635828A5 (de) 1978-08-30 1983-04-29 Ciba Geigy Ag N-substituierte imide und bisimide.
CH641470A5 (de) 1978-08-30 1984-02-29 Ciba Geigy Ag Imidgruppen enthaltende silane.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
DE3432983A1 (de) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituierte 1h-pyrazolo(3,4-b)-pyrazin-derivate und antitumormittel, die diese enthalten
JPS62273979A (ja) 1986-05-21 1987-11-28 Lion Corp 1,5−置換−1H−ピラゾロ〔3,4−b〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
JPS6310630A (ja) 1986-06-23 1988-01-18 Teijin Ltd 芳香族ポリアミドイミドエ−テルの製造法
JPS6317882A (ja) 1986-07-09 1988-01-25 Lion Corp 5−置換−1H−ピラゾロ〔3,4−b〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (de) 1987-10-30 1989-05-18 Bayer Ag N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
JPH029895A (ja) 1988-06-28 1990-01-12 Lion Corp ヌクレオシド類似化合物及び抗腫瘍剤
DD280853A1 (de) 1989-03-21 1990-07-18 Akad Nauk Sssr Bindemittel fuer elektroden, vorzugsweise fuer polymerelektroden
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (ja) 1989-07-17 1999-01-13 三井化学株式会社 イミド環を有する新規ジフェノール類およびその製造方法
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (de) 1989-11-11 1991-05-16 Bayer Ag Heterocyclische verbindungen und deren verwendung als pigmente und farbstoffe
US5329046A (en) 1989-12-28 1994-07-12 Hoechst Aktiengesellschaft Biscationic acid amide and imide derivatives and processes for their preparation
CA2072560A1 (en) 1989-12-28 1991-06-29 Hans-Tobias Macholdt Biscationic acid amide and acid imide derivatives as charge controllers
JP2883670B2 (ja) 1990-03-23 1999-04-19 三井化学株式会社 イミド環を有する新規ビスフェノール類およびその製造方法
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
NZ240089A (en) 1990-10-03 1993-04-28 Commw Scient Ind Res Org Diaminobisimide compounds and compositions comprising such compounds for curing epoxy resins
JPH04158084A (ja) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd 記録材料
JPH04179576A (ja) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd 記録材料
JPH04328121A (ja) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd 半導体封止用エポキシ樹脂組成物
KR100207360B1 (ko) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
DE4119767A1 (de) 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (ja) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 ヒドロシリル基含有イミド化合物
JP3232123B2 (ja) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 硬化性組成物
WO1993024488A1 (en) 1992-05-28 1993-12-09 Commonwealth Scientific And Industrial Research Organisation Bismaleimide compounds
JPH08504196A (ja) 1992-12-07 1996-05-07 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション ビスナドイミド
EP0678106A4 (en) 1993-01-11 1995-12-27 Univ Pennsylvania POLYCYCLIC AROMATIC COMPOUNDS WITH NON-LINEAR OPTICAL PROPERTIES.
WO1994025438A1 (en) 1993-04-28 1994-11-10 The Du Pont Merck Pharmaceutical Company Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
CA2276946A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions containing the same
EP0746320B1 (en) 1994-02-02 2001-01-31 Eli Lilly And Company Hiv protease inhibitors and intermediates
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (ja) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc 結晶化促進剤
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
TR199900228T2 (xx) 1996-08-06 1999-03-22 Pfizer Inc. �kameli/katk�l� pirido-veya pirimido-i�eren 6,6-veya 6,7-bisiklik t�revler.
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP3669783B2 (ja) 1996-08-21 2005-07-13 三井化学株式会社 有機電界発光素子
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式2−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
JP2001521523A (ja) 1997-04-11 2001-11-06 アボツト・ラボラトリーズ 化学的シナプス伝達の制御において有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
AU751188C (en) 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
JP2001512742A (ja) 1997-08-11 2001-08-28 シーオーアール セラピューティクス インコーポレイテッド 選択的Xa因子阻害剤
WO1999009030A1 (en) 1997-08-20 1999-02-25 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (ja) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd 縮合ヘテロ環化合物
KR20010041109A (ko) 1998-02-20 2001-05-15 다케다 야쿠힌 고교 가부시키가이샤 아미노구아니딘 히드라존 유도체, 이의 제조방법 및 이의약제
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
EP1080092B1 (en) 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
WO1999064400A1 (en) 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
JP2000123973A (ja) 1998-10-09 2000-04-28 Canon Inc 有機発光素子
AU769989B2 (en) 1998-10-23 2004-02-12 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (de) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19920790A1 (de) 1999-05-06 2000-11-09 Bayer Ag Bis-Sulfonamide mit anti-HCMV-Wirkung
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP4041624B2 (ja) 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
PL207590B1 (pl) 1999-09-24 2011-01-31 Janssen Pharmaceutica Nv Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
ATE349447T1 (de) 1999-10-21 2007-01-15 Hoffmann La Roche Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren
RU2265606C2 (ru) 1999-10-21 2005-12-10 Ф.Хоффманн-Ля Рош Аг ГЕТЕРОАЛКИЛАМИНОЗАМЕЩЕННЫЕ БИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ГЕТЕРОЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ р38
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EP1242382B1 (en) 1999-12-29 2007-02-07 Wyeth Tricyclic protein kinase inhibitors
OA12316A (en) 2000-01-24 2006-05-15 Warner Lambert Co 3-Aminoquinazolin-2,4-dione antibacterial agents.
CN1433417A (zh) 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
WO2001057037A1 (en) 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
ES2241781T3 (es) 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7498335B2 (en) 2000-03-06 2009-03-03 Astrazeneca Ab Method of producing an antiangiogenic or vascular permeability reducing effect
DE10012549A1 (de) 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
JP2001265031A (ja) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び、電子写真装置
KR100901221B1 (ko) 2000-04-28 2009-06-08 아카디아 파마슈티칼스 인코포레이티드 무스카린성 작용제
CA2408156A1 (en) 2000-05-05 2001-11-15 Millennium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001268712A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
AU2001285401A1 (en) 2000-08-07 2002-02-18 Neurogen Corporation Heterocyclic compounds as ligands of the GABAa receptor
ATE320427T1 (de) 2000-08-14 2006-04-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
MXPA03001963A (es) 2000-09-06 2004-03-18 Johnson & Johnson Un metodo para tratar alergias usando pirazoles sustituidos.
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (ja) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 熱現像カラー画像記録材料
ATE449763T1 (de) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
JP4310109B2 (ja) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
US7279474B2 (en) 2001-04-30 2007-10-09 Glaxo Group Limited Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF)
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MXPA03009894A (es) 2001-06-19 2004-02-17 Warner Lambert Co Agentes antibacterianos.
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
US7205417B2 (en) 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
DE60230890D1 (de) 2001-09-19 2009-03-05 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
CN1582284A (zh) 2001-11-07 2005-02-16 霍夫曼-拉罗奇有限公司 氨基嘧啶类和吡啶类化合物
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
BRPI0308208B8 (pt) 2002-03-05 2021-05-25 Axys Pharm Inc compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
RU2310657C2 (ru) 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
CN100396670C (zh) 2002-05-15 2008-06-25 詹森药业有限公司 作为pdfg受体抑制剂的n-取代的3-氨基苯并环戊二烯并吡唑及药用组合物和用途
JP4499342B2 (ja) 2002-05-16 2010-07-07 株式会社カネカ SiH基を含有する含窒素有機系化合物の製造方法
PT1551834E (pt) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
DE60330466D1 (de) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CN100432073C (zh) 2002-08-06 2008-11-12 霍夫曼-拉罗奇有限公司 作为p-38map激酶抑制剂的6-烷氧基-吡啶并-嘧啶
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
MXPA05005028A (es) 2002-11-18 2005-08-03 Hoffmann La Roche Diazinopirimidinas.
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
AU2003298034B2 (en) 2002-12-06 2011-04-21 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
JP4666256B2 (ja) 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Pd−1に対する抗体およびその使用
JP2004203749A (ja) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd SiH基を含有する含窒素有機系化合物の製造方法
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
WO2004099209A1 (en) 2003-05-05 2004-11-18 F. Hoffmann-La-Roche Ag Fused pyrimidine derivatives with crf activity
JP2004346145A (ja) 2003-05-21 2004-12-09 Teijin Ltd イミド組成物およびそれからなる樹脂組成物、及びその製造方法
WO2004112793A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
NZ543636A (en) 2003-06-06 2009-07-31 Arexis Ab Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
JP4631703B2 (ja) 2003-06-18 2011-02-16 宇部興産株式会社 ピリミジン−4−オン化合物の製造方法
JP2005015395A (ja) 2003-06-26 2005-01-20 Japan Science & Technology Agency 新規ピリミドピリミジンヌクレオシドとその構造類縁体
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Hsp90-저해제로서의 신규 헤테로시클릭 화합물
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
EP1670761B1 (en) 2003-10-01 2009-01-28 Xention Limited Tetrahydro-naphthalene and urea derivatives
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
ATE444068T1 (de) 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
AU2005206562A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20060019952A1 (en) 2004-01-29 2006-01-26 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AU2005214352B2 (en) 2004-02-14 2009-11-12 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
RU2006134021A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные гетероарил-конденсированного пиразола
KR100843526B1 (ko) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
WO2005085210A1 (ja) 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
EP1736476A4 (en) 2004-03-29 2010-04-07 Mitsui Chemicals Inc NEW CONNECTION AND ORGANIC ELECTRONIC DEVICE USING SUCH A CONNECTION
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (ja) 2004-05-10 2005-11-17 Mitsui Chemicals Inc テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
EP1761539A1 (en) 2004-06-02 2007-03-14 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
EP1758892B1 (en) 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
SI2298768T1 (en) 2004-06-11 2013-01-31 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (ja) 2004-07-12 2006-02-02 Mitsui Chemicals Inc テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
ATE425166T1 (de) 2004-08-31 2009-03-15 Hoffmann La Roche Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
AU2005279337A1 (en) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2006024834A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
DE102004042667A1 (de) 2004-09-01 2006-03-30 Ewald Dörken Ag Mehrschichtige Gebäudewand
KR101165653B1 (ko) 2004-09-10 2012-07-17 우베 고산 가부시키가이샤 변성 폴리이미드 수지 및 경화가능 수지 조성물
AU2005336092B2 (en) 2004-09-14 2010-05-27 Cynthia C. Bamdad Methods for diagnosis and treatment of cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060135553A1 (en) 2004-10-28 2006-06-22 Campbell David A Imidazole derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
JP2008519036A (ja) 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
CA2587153A1 (en) 2004-11-18 2006-05-26 Incyte Corporation Inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type 1 and methods of using the same
RU2394825C2 (ru) 2004-11-22 2010-07-20 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиразины, пригодные в качестве ингибиторов киназы аврора а
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20100152206A1 (en) 2005-01-07 2010-06-17 Ralph Mazitschek Bicyclic Dihydropyrimidines and Uses Thereof
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
US20090111837A1 (en) 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
JP2006284843A (ja) 2005-03-31 2006-10-19 Mitsui Chemicals Inc テトラカルボン酸誘導体を用いた電子写真感光体、電子写真装置
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (ja) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd 高コンダクタンス型カルシウム感受性kチャネル開口薬
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2006124731A2 (en) * 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
JP5016593B2 (ja) 2005-05-13 2012-09-05 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテイン・キナーゼ阻害剤としての化合物および組成物
WO2006135821A2 (en) 2005-06-09 2006-12-21 Achille Carlisle Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ATE482958T1 (de) 2005-08-09 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
BRPI0614578A2 (pt) 2005-08-16 2011-04-05 Irm Llc composto, composição farmacêutica como inibidores de proteìna cinases, bem como seu método e uso
CN101242832B (zh) 2005-08-25 2011-08-10 霍夫曼-拉罗奇有限公司 用作p38 MAP激酶抑制剂的稠合吡唑
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
AU2006287771A1 (en) 2005-09-06 2007-03-15 Smithkline Beecham Corporation Regioselective process for preparing benzimidazole thiophenes
KR20080046728A (ko) 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 복소환 화합물, 그의 제조 방법 및 용도
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
CN101309925A (zh) 2005-09-23 2008-11-19 先灵公司 作为治疗药物的稠合四环类代谢型谷氨酸受体1拮抗剂
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CN102746298A (zh) 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
EP1943231A1 (en) 2005-10-26 2008-07-16 Boehringer Ingelheim International Gmbh (hetero)aryl compounds with mch antagonistic activity and medicaments comprising these compounds
MX362412B (es) 2005-11-01 2019-01-15 Targegen Inc Inhibidores de biaril meta-pirimidina de cinasas.
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007056075A2 (en) 2005-11-02 2007-05-18 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
ES2401099T3 (es) 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
EP2314590A1 (en) 2005-11-10 2011-04-27 ChemoCentryx, Inc. Substituted quinolones and methods of use
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
CN101466710B (zh) 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP2009519908A (ja) 2005-12-08 2009-05-21 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害活性を有する二環式化合物
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
EP1968950A4 (en) 2005-12-19 2010-04-28 Genentech Inc PYRIMIDINKINASEINHIBITOREN
AU2006326989B2 (en) 2005-12-21 2011-11-24 Novartis Ag Pyrimidinyl aryl urea derivatives being FGF inhibitors
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007092879A2 (en) 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Tlr7変調剤としての3−デアザプリン誘導体
WO2007109334A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. Sip receptor modulating compounds and use thereof
CA2680789C (en) 2006-03-28 2016-02-16 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
CA2648324A1 (en) 2006-04-06 2007-10-18 Wisconsin Alumni Research Foundation 2-methylene-1.alpha.,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
US20090286813A1 (en) 2006-04-13 2009-11-19 Astrazeneca Ab Thioxanthine Derivatives and Their Use as Inhibitors of MPO
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
JP5241704B2 (ja) 2006-05-11 2013-07-17 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
RU2008149245A (ru) 2006-05-15 2010-06-20 Айрм Ллк (Bm) Композиции и способы ингибирования рецепторных киназ fgf
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
AU2007262670B2 (en) 2006-06-22 2012-12-20 Prana Biotechnology Limited Method of treatment of glioma brain tumour
US20090281115A1 (en) 2006-06-30 2009-11-12 Board of Regents, The University of Texas System, a Texas University Inhibitors of c-kit and uses thereof
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
PL2061765T3 (pl) 2006-09-01 2015-04-30 Senhwa Biosciences Inc Modulatory białkowych kinaz serynowo-treoninowych i PARP
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
EP2270200A3 (en) 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
JP5372759B2 (ja) 2006-09-21 2013-12-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
TW200836724A (en) 2006-09-22 2008-09-16 Glaxo Group Ltd Novel compounds
CA2664375A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008052934A1 (en) 2006-10-30 2008-05-08 Glaxo Group Limited Novel substituted pyrimidines as cysteine protease inhibitors
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
WO2008063583A1 (en) 2006-11-17 2008-05-29 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (ko) 2006-11-20 2008-05-23 에스케이케미칼주식회사 피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물
EP3443958A1 (en) 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
MX2009006466A (es) 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
KR20090117730A (ko) 2007-01-08 2009-11-12 폴리에라 코퍼레이션 아렌-비스(디카르복스이미드)-기재 반도체 물질, 및 이를 제조하기 위한 관련된 중간체의 제조 방법
CN101007778A (zh) 2007-01-10 2007-08-01 复旦大学 一种链延长型芴基双马来酰亚胺及其制备方法
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
WO2008084861A1 (ja) 2007-01-12 2008-07-17 Astellas Pharma Inc. 縮合ピリジン化合物
FR2911604B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja) 2007-02-06 2013-12-04 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
JP2008198769A (ja) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd 有機エレクトロルミネッセント素子
CA2678492A1 (en) 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
US20080221128A1 (en) 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a squaramide moiety
RU2498983C2 (ru) 2007-03-12 2013-11-20 Юм Биосайнсес Аустралия Пти Лтд Соединения фениламинопиримидина и их применения
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (ko) 2007-04-10 2008-10-15 에스케이케미칼주식회사 락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
US20100112211A1 (en) 2007-04-12 2010-05-06 Advanced Technology Materials, Inc. Zirconium, hafnium, titanium, and silicon precursors for ald/cvd
CN101754961A (zh) 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのキノキサリン誘導体
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
JP5622568B2 (ja) 2007-06-03 2014-11-12 バンダービルト ユニバーシティ ベンズアミドmGluR5の正のアロステリック調節因子ならびにその作製および使用方法
JP2010529120A (ja) 2007-06-07 2010-08-26 メルク・シャープ・エンド・ドーム・コーポレイション 三環式アニリド複素環cgrp受容体アンタゴニスト
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
SI2168966T1 (sl) 2007-06-15 2017-03-31 Msd K.K. Derivat biciklo anilina
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
CA2694261A1 (en) 2007-07-26 2009-01-29 Novartis Ag Organic compounds
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害薬としてのキノキサリン誘導体
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
JP5792955B2 (ja) 2007-10-01 2015-10-14 アイシス ファーマシューティカルズ, インコーポレーテッド 線維芽細胞増殖因子受容体4発現のアンチセンスモジュレーション
AU2008308092B2 (en) 2007-10-05 2013-07-11 Msd K.K. Benzoxazinone derivative
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US8513233B2 (en) 2007-10-11 2013-08-20 Shanghai Institute Of Materia Medica, Cas Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
JP5273052B2 (ja) 2007-10-13 2013-08-28 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
CA2702838A1 (en) 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
ES2393430T3 (es) 2007-10-17 2012-12-21 Novartis Ag Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
MX2010005671A (es) 2007-11-28 2010-06-25 Dana Farber Cancer Inst Inc Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso.
JP2011505407A (ja) 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US20100331333A1 (en) 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2009086509A2 (en) 2007-12-27 2009-07-09 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
US20100292188A1 (en) 2008-01-24 2010-11-18 Ucb Pharma S.A. Compounds Comprising A Cyclobutoxy Group
EP2248814A4 (en) 2008-01-24 2011-01-12 Alla Chem Llc SUBSTITUTED CYCLOALKAN [E AND D] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND PROCESS FOR THEIR PREPARATION AND THEIR USE
KR20100119776A (ko) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 2-알킬아미노-3-아릴설포닐-사이클로알카노[e 또는 d]피라졸로[1,5-A]피리미딘/세로토닌 5-HT6 수용체의 길항제, 이의 제조방법 및 이의 용도
WO2009094528A1 (en) 2008-01-25 2009-07-30 High Point Pharmaceuticals, Llc TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
CN101981037B (zh) 2008-01-30 2013-09-04 吉宁特有限公司 吡唑并嘧啶pi3k抑制剂化合物及使用方法
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2−アミノピリジン系キナーゼ阻害薬
JP2011513233A (ja) 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Gpr119活性モジュレーターとしての化合物および組成物
BRPI0907577A2 (pt) 2008-02-22 2015-07-21 Hoffmann La Roche Moduladores para amiloide beta
JP5451646B2 (ja) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
ITTV20080039A1 (it) 2008-03-06 2009-09-07 Alpinestars Research Srl Collare di protezione in particolare per guidatori di motoveicoli
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (ja) 2008-04-11 2009-10-15 第一三共株式会社 アミノシクロヘキシル誘導体
WO2009125809A1 (ja) 2008-04-11 2009-10-15 第一三共株式会社 ピペリジン誘導体
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
JP5539963B2 (ja) 2008-04-29 2014-07-02 ノバルティス アーゲー 線維芽細胞増殖因子受容体のキナーゼ活性のモジュレーションをモニタリングする方法、および該方法の使用
CN102015704A (zh) 2008-04-29 2011-04-13 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
MY155535A (en) 2008-05-23 2015-10-30 Novartis Ag Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
AU2009255358A1 (en) 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
CN102089403A (zh) 2008-06-10 2011-06-08 巴斯夫欧洲公司 新型过渡金属配合物及其在有机发光二极管中的用途-ⅲ
FR2932600B1 (fr) 2008-06-11 2010-06-04 Areva Np Embout inferieur d'assemblage de combustible nucleaire
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
KR20110020904A (ko) 2008-06-19 2011-03-03 아스트라제네카 아베 피라졸 화합물 436
TW201004958A (en) 2008-06-24 2010-02-01 Res Found Itsuu Lab Oxazolidinone derivatives having a fused ring
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5640006B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド ヒストン脱アセチル化酵素および/またはサイクリン依存性キナーゼの縮合複素環式阻害剤
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
CA2730593A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010009207A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
WO2010030027A1 (en) 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
EP2342226B1 (en) 2008-09-26 2016-06-22 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
AR073760A1 (es) 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
WO2010045371A1 (en) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32203A (es) 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
ES2548141T3 (es) 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
JP5522053B2 (ja) 2008-12-03 2014-06-18 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CA2746220A1 (en) 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
JP2012511501A (ja) 2008-12-12 2012-05-24 Msd株式会社 ジヒドロピリミドピリミジン誘導体
ES2544452T3 (es) 2008-12-19 2015-08-31 Genentech, Inc. Compuestos heterocíclicos y métodos de uso
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US8592425B2 (en) 2009-01-16 2013-11-26 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
DE102009007038A1 (de) 2009-02-02 2010-08-05 Merck Patent Gmbh Metallkomplexe
JP2010180147A (ja) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc シアン酸エステル化合物、およびその硬化物
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
WO2010104047A1 (ja) 2009-03-11 2010-09-16 国立大学法人京都大学 多環芳香族化合物
EP2408744A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
EA020825B1 (ru) 2009-04-07 2015-02-27 Эмерити Фарма Аб Аналоги изоксазол-3(2h)-она в качестве терапевтических агентов
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (ja) 2009-04-20 2014-06-25 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置および照明装置
ES2347630B1 (es) 2009-04-29 2011-09-08 Universitat Ramon Llull Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
JP5600891B2 (ja) 2009-05-15 2014-10-08 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置および照明装置
JP5604808B2 (ja) 2009-05-20 2014-10-15 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5568889B2 (ja) 2009-05-22 2014-08-13 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置、照明装置及び有機エレクトロルミネッセンス素子材料
JP5629980B2 (ja) 2009-05-22 2014-11-26 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
EP2435472A1 (en) 2009-05-27 2012-04-04 Københavns Universitet Fibroblast growth factor receptor-derived peptides binding to ncam
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (ja) 2009-06-24 2014-10-08 コニカミノルタ株式会社 白色有機エレクトロルミネッセンス素子、表示装置及び照明装置
SMT201700430T1 (it) 2009-06-25 2018-01-11 Alkermes Pharma Ireland Ltd Composti eterociclici per il trattamento di disturbi neurologici e psicologici
WO2011002038A1 (ja) 2009-06-30 2011-01-06 日本ゼオン株式会社 新規なジアリールアミン化合物、並びに、老化防止剤、ポリマー組成物、ゴム架橋物、及び、その成形品、並びに、ジアリールアミン化合物の製造方法
JPWO2011007819A1 (ja) 2009-07-17 2012-12-27 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (fr) 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
BR112012002331A2 (pt) 2009-08-05 2019-09-24 Versitech Ltd composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
WO2011016528A1 (ja) 2009-08-07 2011-02-10 中外製薬株式会社 アミノピラゾール誘導体
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
JP5577650B2 (ja) 2009-08-24 2014-08-27 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101184115B1 (ko) 2009-08-31 2012-09-18 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
KR101650981B1 (ko) 2009-09-03 2016-08-24 바이오에너제닉스 Pask의 억제를 위한 복소환 화합물
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US9481675B2 (en) 2009-09-11 2016-11-01 Merck Sharp & Dohme Corp. Gyrase inhibitors
WO2011035376A1 (en) 2009-09-24 2011-03-31 Romar Engineering Pty Ltd A mould or mould core and a method of manufacturing a mould or mould core
US8426438B2 (en) 2009-10-01 2013-04-23 Merck Sharp & Dohme Corp. Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
KR20110043270A (ko) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 유기발광화합물 및 이를 구비한 유기발광소자
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
WO2011051425A1 (en) 2009-10-30 2011-05-05 Novartis Ag N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
CN102695417A (zh) 2009-11-06 2012-09-26 普莱希科公司 用于激酶调节的化合物和方法及其适应症
JP5740409B2 (ja) 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
RU2012127368A (ru) 2009-12-01 2014-01-10 Эбботт Лэборетриз Новые трициклические соединения
JP2011116840A (ja) 2009-12-02 2011-06-16 Fujifilm Corp 顔料微粒子分散体、これを用いた光硬化性組成物及びカラーフィルタ
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US8759366B2 (en) 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
EP2512476A1 (en) 2009-12-18 2012-10-24 Novartis AG Method for treating haematological cancers
ES2842399T3 (es) 2009-12-22 2021-07-14 Vertex Pharma Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US20130096115A1 (en) 2009-12-28 2013-04-18 Afraxis, Inc. Methods for treating autism
JP2013515785A (ja) 2009-12-29 2013-05-09 ポリエラ コーポレイション 有機半導体としてのチオン酸化芳香族ビスイミドおよびそれを組み込む装置
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
EP2519525A4 (en) 2009-12-30 2013-06-12 Arqule Inc SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
CN102115026A (zh) 2009-12-31 2011-07-06 清华大学 一维纳米结构、其制备方法及一维纳米结构作标记的方法
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AR079975A1 (es) 2010-01-06 2012-03-07 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
DE112011100604T5 (de) 2010-02-18 2013-01-31 Ntn Corporation Verdicker, Schmierfett, Verfahren zur Herstellung derselben und fettgeschmiertes Lager
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
JP5662994B2 (ja) 2010-02-26 2015-02-04 新日鉄住金化学株式会社 有機電界発光素子
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
KR20130006664A (ko) 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. 인다졸 화합물 및 그의 용도
EP2550266B1 (en) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011123493A1 (en) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (zh) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
JP5724204B2 (ja) 2010-04-07 2015-05-27 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置、及び照明装置
US8618095B2 (en) 2010-04-13 2013-12-31 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
CN102844031A (zh) 2010-04-16 2012-12-26 诺华有限公司 用于治疗肝癌的有机化合物
ES2545811T3 (es) 2010-04-22 2015-09-16 Janssen Pharmaceutica Nv Compuestos de indazol útiles como inhibidores de quetohexoquinasa
BR112012026641A2 (pt) 2010-04-23 2016-07-12 Kineta Inc compostos antivirais
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8481555B2 (en) 2010-04-30 2013-07-09 Bristol-Myers Squibb Company Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
EP2569012A4 (en) 2010-05-11 2013-10-30 Aveo Pharmaceuticals Inc ANTI-FGFR2 ANTIBODY
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
WO2011143475A1 (en) 2010-05-12 2011-11-17 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101486782B1 (ko) 2010-06-27 2015-01-28 킹 사우드 유니버시티 무한 중첩된 해시 체인들에 의한 1회용 패스워드 인증
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
DE102010031127A1 (de) 2010-07-08 2012-01-12 Endress + Hauser Flowtec Ag Messaufnehmer eines thermischen Durchflussmessgeräts zur Ermittlung des Durchflusses eines Mediums durch ein Messrohr und Verfahren zu dessen Herstellung
AU2011276955B2 (en) 2010-07-09 2014-11-06 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20130210807A1 (en) 2010-07-14 2013-08-15 Nigel J Liverton Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors.
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
CN103003262A (zh) 2010-07-16 2013-03-27 协和发酵麒麟株式会社 含氮芳香族杂环衍生物
WO2012008564A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
JP2013539206A (ja) 2010-07-30 2013-10-17 ローム・アンド・ハース・エレクトロニック・マテリアルズ・コリア・リミテッド 発光材料として電界発光化合物を使用する電界発光素子
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
KR101837223B1 (ko) 2010-09-01 2018-03-09 질레드 코네티컷 인코포레이티드 피리디논/피라지논, 그의 제조 방법 및 사용 방법
KR101864908B1 (ko) 2010-09-01 2018-06-05 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2548036T3 (es) 2010-09-08 2015-10-13 Glaxosmithkline Intellectual Property Development Limited Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
KR20130103503A (ko) 2010-09-14 2013-09-23 호도가야 가가쿠 고교 가부시키가이샤 전하 제어제 및 그것을 사용한 토너
CN102399233B (zh) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 PI3K和mTOR双重抑制剂类化合物
CN102399220A (zh) 2010-09-15 2012-04-04 黄振华 三并环类PI3K和mTOR双重抑制剂
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8937077B2 (en) 2010-10-22 2015-01-20 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
JP2012092049A (ja) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd 有害動物防除組成物及び有害動物の防除方法
EP2632466A4 (en) 2010-10-29 2014-03-19 Univ Emory CHINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF AND USES THEREOF
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
US20120115903A1 (en) 2010-11-10 2012-05-10 Gruenenthal Gmbh Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JP2012116825A (ja) 2010-11-11 2012-06-21 Ehime Univ アセンジイミド化合物の製造方法
KR101171232B1 (ko) 2010-11-15 2012-08-06 단국대학교 산학협력단 스파이로 화합물 및 이를 포함하는 유기전계 발광소자
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012068343A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
AU2011330730B2 (en) 2010-11-18 2016-02-18 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
AU2011347711B2 (en) 2010-12-20 2017-02-02 Merck Serono S.A. Indazolyl triazole derivatives as IRAK inhibitors
BR112013015859A2 (pt) 2010-12-22 2018-11-21 Leo Laboratories Ltd composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
JP5845283B2 (ja) 2010-12-22 2016-01-20 レオ・ラボラトリーズ・リミテッドLeo Laboratories Limited インゲノール−3−アシラートiiiおよびインゲノール−3−カルバメート
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
MX2013007261A (es) 2010-12-23 2013-11-04 Amgen Inc Compuestos heterociclicos y sus usos.
JP5691508B2 (ja) 2010-12-27 2015-04-01 Jnc株式会社 ジイミド化合物ならびにインクジェット用インクおよびその用途
KR101466150B1 (ko) 2010-12-31 2014-11-27 제일모직 주식회사 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
EP2662378B1 (en) 2011-01-06 2018-10-10 JX Nippon Oil & Energy Corporation Imide compound, method for producing same, thickening agent for grease, and grease composition
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012112961A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating hypertension
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
PH12013501878A1 (en) 2011-03-17 2013-10-14 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
MX342240B (es) 2011-04-07 2016-09-21 Genentech Inc Anticuerpos anti-fgfr4 y metodos de uso.
FR2974088A1 (fr) 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
EP2710035B1 (en) 2011-05-16 2017-04-12 F. Hoffmann-La Roche AG Fgfr1 agonists and methods of use
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
US20150182525A1 (en) 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Mek抑制劑與奧諾拉(aurora)a激酶選擇性抑制劑之組合
US9543524B2 (en) 2011-06-13 2017-01-10 Lg Chem, Ltd. Compounds and organic electronic device using same
EP2723748B1 (en) 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
WO2013024002A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
JP2013049251A (ja) 2011-08-31 2013-03-14 Fujifilm Corp レーザー彫刻用レリーフ印刷版原版、並びに、レリーフ印刷版及びその製版方法
WO2013033981A1 (zh) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 一类2,7-萘啶衍生物及其制备方法和应用
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
CN103814029B (zh) 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
CA2862895A1 (en) 2011-09-30 2013-04-04 Kineta, Inc. Anti-viral compounds
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
CA2850394C (en) 2011-10-12 2019-05-21 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (ko) 2011-10-20 2018-10-23 에스에프씨 주식회사 유기금속 화합물 및 이를 포함하는 유기전계발광소자
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
WO2013088266A1 (en) 2011-12-13 2013-06-20 Ecolab Usa Inc. Concentrated warewashing compositions and methods
FR2985257B1 (fr) 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr) 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
WO2013109027A1 (ko) 2012-01-18 2013-07-25 덕산하이메탈(주) 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
MX351513B (es) 2012-01-19 2017-10-17 Taiho Pharmaceutical Co Ltd Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
CN104136439B (zh) 2012-02-23 2017-01-18 拜耳知识产权有限责任公司 取代的苯并噻吩基‑吡咯并三嗪及其用途
JP2013179181A (ja) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd 有機光電変換素子
PE20141974A1 (es) 2012-03-14 2014-12-12 Lupin Ltd Compuestos de heterociclilo
KR102126092B1 (ko) 2012-03-30 2020-06-24 노파르티스 아게 저인산혈증성 장애의 치료에 사용하기 위한 fgfr 억제제
JP5120580B1 (ja) 2012-05-14 2013-01-16 Jsr株式会社 液晶配向剤
US10292816B2 (en) 2012-05-20 2019-05-21 Tel Hashomer Medical Research Infrastructure And Services Ltd. Prosthetic mitral valve
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
CA2878251A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病性三環式化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
KR101985259B1 (ko) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 액정 배향제 및 화합물
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (ko) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
WO2014089913A1 (zh) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
KR102030587B1 (ko) 2013-01-09 2019-10-10 에스에프씨주식회사 두 개의 나프틸기를 포함하는 비대칭 안트라센 유도체 및 이를 포함하는 유기 발광 소자
EP2945623B1 (en) 2013-01-15 2018-09-05 Suzhou Kintor Pharmaceuticals, Inc. Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (zh) 2013-01-15 2017-05-31 苏州开拓药业股份有限公司 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
KR101456626B1 (ko) 2013-02-01 2014-11-03 대영이앤비 주식회사 냉장고 부압 방지 장치
JP6311093B2 (ja) 2013-03-07 2018-04-18 国立大学法人九州大学 超分子複合体、発光体、および有機化合物検出用のセンサー素子
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9771327B2 (en) 2013-03-13 2017-09-26 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
MX2015012008A (es) 2013-03-14 2016-04-15 Abbvie Deutschland Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
MX374558B (es) 2013-03-15 2025-03-06 Sanofi Sa Compuestos de heteroarilo y sus usos.
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
KR101573611B1 (ko) 2013-04-17 2015-12-01 주식회사 엘지화학 플러렌 유도체, 이를 이용한 유기 태양 전지 및 이의 제조 방법
WO2014170063A1 (en) 2013-04-19 2014-10-23 Covagen Ag Novel bispecific binding molecules with antitumoral activity
CA3130452C (en) 2013-04-19 2023-10-31 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014182829A1 (en) 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
WO2014198942A1 (en) 2013-06-14 2014-12-18 Sanofi Pyrazolopyridine derivatives for use in the treatment of bladder cancer
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
SG11201600147TA (en) 2013-06-28 2016-02-26 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
RU2016103149A (ru) 2013-07-02 2017-08-07 Зингента Партисипейшнс Аг Пестицидно-активные би-или трициклические гетероциклы с серосодержащими заместителями
WO2015006492A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
JP6018547B2 (ja) 2013-07-09 2016-11-02 大成ロテック株式会社 舗装機械
AU2014287016B2 (en) 2013-07-11 2018-11-01 Acea Biosciences Inc. Pyrimidine derivatives as kinase inhibitors
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
DK3057943T3 (en) 2013-10-18 2018-07-30 Eisai R&D Man Co Ltd PYRIMIDINE-FGFR4 INHIBITORS
EA028819B1 (ru) 2013-10-25 2018-01-31 Новартис Аг Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
FR3012330B1 (fr) 2013-10-29 2015-10-23 Oreal Composition biphase comprenant un ester d'acide gras et de sucre ou un alkylpolyglucoside liquide, de hlb < 8, et un alcane ramifie en c8-c18
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
CN105524048B (zh) 2014-08-19 2019-11-12 上海海和药物研究开发有限公司 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN104262330B (zh) 2014-08-27 2016-09-14 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MX2017010638A (es) 2015-02-20 2018-05-07 Univ Oregon Health & Science Derivados de sobetiroma.
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016192680A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
SG10201912066SA (en) 2015-07-15 2020-02-27 Protagonist Therapeutics Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
DE112016003168B4 (de) 2015-07-15 2024-08-08 Cabot Corporation Verfahren zum herstellen eines silica-elastomerkomposits, und dieses enthaltende produkte
CN107580598B (zh) 2015-07-15 2020-11-13 豪夫迈·罗氏有限公司 作为代谢型谷氨酸受体调节剂的乙炔基衍生物
CR20220194A (es) 2015-07-30 2022-06-16 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017028314A1 (en) 2015-08-20 2017-02-23 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as erk inhibitors
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SMT202000694T1 (it) 2015-12-22 2021-03-15 Incyte Corp Composti eterociclici come immunomodulatori
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4137489A1 (en) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018041091A1 (en) 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물
KR101755556B1 (ko) 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko) 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
US11242334B2 (en) 2017-08-22 2022-02-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
JP7326276B2 (ja) 2017-12-02 2023-08-15 ガラパゴス・ナムローゼ・フェンノートシャップ 新規化合物及び疾患の治療のためのその医薬組成物
CN112135824B (zh) 2018-03-30 2024-11-05 因赛特公司 作为免疫调节剂的杂环化合物
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
SG11202011165TA (en) 2018-05-11 2020-12-30 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2020037004A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh The history of 5-morpholine-4-yl-pyrazolo[[4,3-Bpyridine and their use
WO2020081898A1 (en) 2018-10-20 2020-04-23 The Johns Hopkins University Non-invasive urinary biomarkers for the detection of urothelial carcinoma of the bladder
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法

Also Published As

Publication number Publication date
AU2020270520A1 (en) 2020-12-17
EP2861595A2 (en) 2015-04-22
UA125503C2 (uk) 2022-04-13
SI3176170T1 (sl) 2019-05-31
LUC00222I2 (hu) 2024-10-04
LT3176170T (lt) 2019-04-25
US20130338134A1 (en) 2013-12-19
DK2861595T3 (en) 2017-02-13
EP3822273B1 (en) 2024-04-10
IL289834B2 (en) 2024-07-01
EP3176170A1 (en) 2017-06-07
PH12019502809A1 (en) 2021-07-26
PL3495367T3 (pl) 2021-04-19
KR20150036044A (ko) 2015-04-07
CN107652289A (zh) 2018-02-02
JP2019178156A (ja) 2019-10-17
NO2021034I1 (no) 2021-09-09
US9611267B2 (en) 2017-04-04
IL276433B (en) 2021-05-31
CN107383009B (zh) 2020-06-09
TW202124382A (zh) 2021-07-01
IL256976A (en) 2018-03-29
IL282622B (en) 2022-02-01
HUE042374T2 (hu) 2019-06-28
AU2019200066B2 (en) 2020-08-27
TW202241898A (zh) 2022-11-01
EP4403216A2 (en) 2024-07-24
PT2861595T (pt) 2017-04-03
TWI706953B (zh) 2020-10-11
SI3495367T1 (sl) 2021-01-29
NL301131I1 (hu) 2021-09-29
CY1121299T1 (el) 2020-05-29
ES2984771T3 (es) 2024-10-31
KR20220080213A (ko) 2022-06-14
PT3176170T (pt) 2019-02-05
HRP20190007T1 (hr) 2019-04-05
HUS2100035I1 (hu) 2021-10-28
EP3495367A1 (en) 2019-06-12
EP2861595B1 (en) 2016-12-21
KR102556118B1 (ko) 2023-07-19
KR20200093696A (ko) 2020-08-05
EP3495367B1 (en) 2020-09-30
PH12014502772B1 (en) 2015-02-02
JP6545863B2 (ja) 2019-07-17
JP2015521600A (ja) 2015-07-30
CL2017001984A1 (es) 2018-03-23
CY1118744T1 (el) 2017-07-12
DK2861595T5 (en) 2018-01-15
PH12014502772A1 (en) 2015-02-02
US20240246974A1 (en) 2024-07-25
DK3176170T3 (en) 2019-01-28
CN104507943A (zh) 2015-04-08
CA2876689C (en) 2022-04-26
US20200377504A1 (en) 2020-12-03
US20170137424A1 (en) 2017-05-18
LTPA2021519I1 (hu) 2021-09-27
IL256976B (en) 2020-08-31
MX359293B (es) 2018-09-24
AU2020270520B2 (en) 2023-01-05
MX2014015192A (es) 2015-08-07
NZ702747A (en) 2017-03-31
SMT202000673T1 (it) 2021-01-05
RS58514B1 (sr) 2019-04-30
SG11201408238WA (en) 2015-01-29
ES2618003T9 (es) 2018-03-02
EA201590005A1 (ru) 2015-05-29
CN104507943B (zh) 2017-11-21
ME03300B (me) 2019-07-20
JP6301321B2 (ja) 2018-03-28
JP2020143142A (ja) 2020-09-10
NZ730134A (en) 2018-07-27
CY2021026I1 (el) 2021-12-31
SMT201700146T1 (it) 2017-05-08
IL282622A (en) 2021-06-30
NZ743274A (en) 2019-07-26
US10131667B2 (en) 2018-11-20
HUE052195T2 (hu) 2021-04-28
AU2013287176C1 (en) 2023-01-19
RS55908B1 (sr) 2017-09-29
AU2019200066A1 (en) 2019-01-24
CN107652289B (zh) 2020-07-21
IL276433A (en) 2020-09-30
BR112014030812A2 (pt) 2017-07-25
PT3495367T (pt) 2020-11-12
EP3176170B1 (en) 2018-11-14
MY188363A (en) 2021-12-04
DK3495367T3 (da) 2020-11-16
PL2861595T3 (pl) 2017-06-30
EP3822273A1 (en) 2021-05-19
IL236078A0 (en) 2015-02-01
ES2618003T8 (es) 2021-08-24
SMT201900040T1 (it) 2019-05-10
HRP20201966T1 (hr) 2021-02-05
HK1212326A1 (zh) 2016-06-10
AU2022291504A1 (en) 2023-02-02
PE20190736A1 (es) 2019-05-23
MX389376B (es) 2025-03-20
CN107383009A (zh) 2017-11-24
KR102140426B1 (ko) 2020-08-04
JP7392096B2 (ja) 2023-12-05
AU2013287176A1 (en) 2015-01-15
WO2014007951A3 (en) 2014-03-06
ECSP22091792A (es) 2023-01-31
IL289834A (en) 2022-03-01
CY2021026I2 (el) 2021-12-31
JP6336665B2 (ja) 2018-06-06
HRP20170430T1 (hr) 2017-06-16
LT2861595T (lt) 2017-02-27
AU2022291504B2 (en) 2024-08-01
AU2024227763A1 (en) 2025-01-02
ES2618003T3 (es) 2017-06-20
JP7646791B2 (ja) 2025-03-17
TWI769529B (zh) 2022-07-01
LT3495367T (lt) 2021-02-25
CA3149881A1 (en) 2014-01-09
NL301131I2 (nl) 2021-10-25
MX2022000517A (es) 2022-05-18
IL236078B (en) 2019-08-29
AR091424A1 (es) 2015-02-04
BR112014030812B1 (pt) 2022-11-08
SG10201610416TA (en) 2017-01-27
EA036592B1 (ru) 2020-11-26
ME02651B (me) 2017-06-20
JP7200170B2 (ja) 2023-01-06
EP4403216A3 (en) 2024-10-16
IL289834B1 (en) 2024-03-01
CL2014003355A1 (es) 2015-06-12
TWI801156B (zh) 2023-05-01
US20210380587A1 (en) 2021-12-09
ES2704744T3 (es) 2019-03-19
LTC2861595I2 (hu) 2023-06-26
KR102406771B1 (ko) 2022-06-13
US20190127376A1 (en) 2019-05-02
CO7240375A2 (es) 2015-04-17
AU2013287176B2 (en) 2018-10-04
RS61089B1 (sr) 2020-12-31
SI2861595T1 (sl) 2017-04-26
US11053246B2 (en) 2021-07-06
PH12019502809B1 (en) 2024-04-24
PL3176170T3 (pl) 2019-05-31
ES2832497T3 (es) 2021-06-10
US11840534B2 (en) 2023-12-12
PE20150684A1 (es) 2015-05-11
JP2024023367A (ja) 2024-02-21
UA117347C2 (uk) 2018-07-25
EP2861595B9 (en) 2017-06-21
JP2023027344A (ja) 2023-03-01
TW201402574A (zh) 2014-01-16
MY171375A (en) 2019-10-10
JP2017222709A (ja) 2017-12-21
JP2018135377A (ja) 2018-08-30
JP6711946B2 (ja) 2020-06-17
CY1123631T1 (el) 2022-03-24
WO2014007951A2 (en) 2014-01-09
CA2876689A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
AU2022291504B2 (en) Substituted tricyclic compounds as fgfr inhibitors